Attached files

file filename
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Medite Cancer Diagnostics, Inc.ex32-1.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Medite Cancer Diagnostics, Inc.ex32-2.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Medite Cancer Diagnostics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Medite Cancer Diagnostics, Inc.ex31-1.htm
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the fiscal year ended December 31, 2017
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________   to _________
 
Commission file number ____
 
MEDITE CANCER DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
36-4296006
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
 
 
4203 SW 34th Street, Orlando, FL
32811
(Address of principal executive offices)
(Zip Code)
 
(407) 996-9630
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
None
 
Not Applicable
 
Securities registered pursuant to Section 12(g) of the Act:
 
Common Stock, $0.001 par value
(Title of class)
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes    No  
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.       Yes    No 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No
 
 Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes    No
 
 
 
 
 
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.   See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  
Accelerated filer                   
 
 
Non-accelerated filer     
Smaller reporting company  
   
   
   
Emerging growth company
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes    No
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
The aggregate market value of the common stock held by non-affiliates of the Company was $5,324,608 based upon the closing price of shares of the Company’s common stock, $0.001 par value per share, of $0.55 as reported on the OTC Bulletin Board on June 30, 2017, the last day of the Company’s most recently completed second fiscal quarter. Shares of common stock held by each current executive officer and director and by each person who is known by the Company to own 5% or more of the outstanding common stock have been excluded from this computation in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not a conclusive determination for other purposes.
 
The number of shares of common stock outstanding as of May 17, 2018 was 56,655,580.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
None.
 
 

 
 
 

MEDITE CANCER DIAGNOSTICS, INC.
Annual Report on Form 10-K
December 31, 2017
 
TABLE OF CONTENTS
 
 
 
 
 
Page
 
 
 
 
 
 
 
1
 
16
 
16
 
16
 
16
 
 
 
 
 
 
17
 
 
 
 
 
17
 
18
 
19
 
23
 
23
 
23
 
24
 
 
 
 
 
 
25
 
 
 
 
 
25
 
28
 
30
 
32
 
34
 
 
 
 
 
 
35
 
 
 
 
 
35
 
36
 
 
 
 
Cautionary Statement Regarding Forward-Looking Statements
 
This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include, but are not limited to: our ability to raise capital; our ability to retain key employees; our ability to engage third party distributors to sell our products; economic conditions; technological advances in the medical field; demand and market acceptance risks for new and existing products, technologies, and healthcare services; the impact of competitive products and pricing; U.S. and international regulatory, trade, and tax policies; product development risks, including technological difficulties; ability to enforce patents; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature.   These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. We do not undertake to update our forward-looking statements.
 
 
 
-ii-
 
PART I
 
Item 1.
Business
 
Overview
 
Overview of MEDITE Cancer Diagnostics, Inc.
 
MEDITE Cancer Diagnostics, Inc. (the “Company”, “MEDITE”, “it”, “we”, or “us”), formerly CytoCore, Inc., develops, manufactures, markets and sells MEDITE branded products (instruments and consumables), in the areas of histology and cytology. These premium medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Depending upon the type of cancer, segments within the current target market of approximately $5.8 billion are growing at annual rates between 10% and 30%. The well-established brand of MEDITE is widely known and remains a professional description of the Company’s business. The Company’s trading symbol is “MDIT”.
 
In 2017 the Company focused on implementation of several growth opportunities including enhanced distribution of core products through focused sales and distribution channels, newly developed patented assays, new laboratory devices and several marketing projects like the introduction of the SureCyte C1 fluorogenic stain worldwide.  The Company has approximately 64 employees in two countries, a distribution network in over 80 countries and a wide range of products for anatomic pathology, histology and cytology laboratories available for sale.
 
China is an important market to the Company and we have addressed several product quality issues described under Revenue and Results of Operations elsewhere within this Report.  The Company has addressed most of the product, service and training issues in China.  Sales in China for 2017 were $85,000 compared to approximately $1 million for 2016.  There are two reasons for the lower number in 2017: 1. Legacy product quality issues from 2016 and early 2017, and 2. Inability to deliver products because of lack of working capital. The Company expects to grow business in China in 2018 and going forward.
 
The Company’s cytology product line (non-Gyn and Gyn applications) revenue was lower in Europe during 2017 because product was not available to ship to meet demand, due to working capital constraints. The Company is in the process of moving forward the submission of an application to the US Food and Drug Administration (“FDA”) for SureThin Gyn applications. The Company will be able to compete with the dominant suppliers in this $600 million market and target major strategic lab partners. The impact of the gynecology segment SureThin solution in the US market will drive significant new revenue and gross margin improvement opportunities moving forward.
  
The patented self-collection device SoftKit targets the growing POC (Point of Care) market. Growth in this area is due to consumer-driven health care requirements and the necessity to support and address incremental patient population needs for screening and ongoing diagnostic tests. SoftKit is planned to be sold through various marketing channels that serve the gynecology consumer health and emerging post-acute care space. The Company is currently developing a study plan with a major research center in the Midwest, with the goal of submitting for FDA approval.
 
Management believes that 2017 developments allowed the Company to more fully leverage the products and biomarker solutions from the original CytoCore component of MEDITE. The first entry is the introduction of the SureCyte C1 fluorogenic instant stain, offering tremendous opportunities for lab efficiencies and enhanced patient care. C1 is the first of many new offerings under the SureCyte brand that will ultimately include algorithms for computer-assisted analysis and advanced assays for micro-environment analysis. The Company is currently conducting informal studies with several labs in the U.S. and Europe and is also conducting a formal study with a hospital in China in partnership with UNIC. CI has recently received the CE Mark in the EU.
 
As part of early SureCyte marketing activities, the Company is working with numerous U.S. and European Key Opinion Leaders (KOLs) and clinical sites to test the C1 stain, provide feedback on the overall product line plans, and to create white papers and publish articles in highly-recognized peer-reviewed journals and conferences.
 
The Company will begin manufacturing its new cryostat line during the second quarter of 2018 and has already taken some customer orders. This enhanced microtome and cryostat product line will allow MEDITE to meet the anticipated demand for these instruments as well as enhance its worldwide distribution channel through its suppliers including China.
 
 
The Company operates in the industry segment for cancer screening, diagnostics instruments and consumables for histology and cytology laboratories.
 
Definition:
Histology - Cancer diagnostics based on the structures of cells in tissues
 
Cytology - Cancer screening and diagnostics based on the structures of individual cells
 
Cancers and precancerous conditions are defined in terms of structural abnormalities in cells. For this reason, cytology is widely used for the detection of such conditions while histology is typically used for the confirmation, identification and characterization of the cellular abnormalities detected by cytology. Other diagnostic methods such as marker-based assays provide additional information that can supplement, but which cannot replace cytology and histology. The trend towards more personalized treatment of cancer increases the need for cytology, histology and assays for identifying and testing the best treatment alternatives. The Company believes that this segment will therefore be increasingly important for future development of strategies to fight the “cancer epidemic” (World Health Organization: World Cancer Report 2014) which expects about a 50 % increase in cancer cases worldwide within the next 20 years.
 
This segment sees a trend toward, and demand for, higher automation for more throughput in bigger laboratories, process standardization, digitalization of cell and tissue slides and computer-aided diagnostic systems, and in general a search for more cost-effective solutions.
 
MEDITE acts as a one-stop-shop for histology (also known as anatomic pathology) laboratories either as part of a hospital, as part of a chain of laboratories or individually. It is one out of only four companies offering all equipment and consumables for these laboratories worldwide. The MEDITE brand stands for innovative and high-quality products – most equipment is made in Germany – and competitive pricing.
 
For the cytology market, MEDITE offers a wide range of consumable products and equipment; in particular for liquid-based-cytology which is an important tool in cancer screening and detection in the field of cervical, bladder, breast, lung and other cancer types.
 
All of the Company’s operations during the reporting period were conducted and managed within this segment, with management team reporting directly to the Chief Executive Office. For information on revenues, profit or loss and total assets, among other financial data, attributable to operations, see the consolidated financial statements included herein. Further during 2017 the Company added key personnel with excellent historical performance in new product commercialization, sales development and internal operations improvement.
 
Outlook
 
Due to promising innovative new products for cancer risk assessment and an increasing number of distribution contracts executed in recent years, management believes the profitability and cash-flow of the business will grow and improve. Significant on-going manufacturing issues have been identified and addressed, and additional operating expenditures may be necessary to manufacture and market new and existing products to achieve the accelerated sales growth targets outlined in the Company’s business plan. To realize the planned growth potential, management will focus its efforts on 1.) Finishing and gaining approval for the products currently under development, 2.) Increasing sales in the U.S. to optimize the excellent sales/distribution channels available there and 3.) Invigorate the distribution networks for EU/ROW and continue to expand Chinese market sales by broadening the Company’s collaboration with the local distributor UNIC. The Company also will work on continuously optimizing manufacturing capacity and planning to increase gross margin. Implementation of these plans are contingent upon securing additional debt and/or equity financing, which was partly completed through May 2018 (see Subsequent Events). If the Company is unable to obtain additional capital or generate profitable sales revenues, we may be required to curtail product development and other activities. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty.
 
Currently, the Company’s sales are primarily generated in Euro currency. In 2017 the average EUR-USD exchange rate was 1.129507 compared to 1.10730 for 2016 (ODNDA) a significant increase. The stronger Euro (and increasing lately to 1.19 against USD) is favorable to revenue reporting since 90% of the Company’s revenue is in Euro, but also increases COGS for products sold in the U.S. and other countries conducting business in USD (including China). Overall, the stronger Euro is favorable to revenue reporting.
  
 
 
Background
 
The Company was incorporated in Delaware in December 1998 as the successor to Bell National Corporation, a company incorporated in California in 1958. In December 1998, Bell National, which was then a shell corporation, acquired InPath, LLC, a development stage company engaged in the design and development of products used in screening for cervical and other types of cancer. For accounting purposes, the acquisition was treated as if InPath had acquired Bell National. However, Bell National continued as the legal entity and the registrant for Securities and Exchange Commission (“SEC”) filing purposes. Bell National merged into Ampersand Medical Corporation, its wholly-owned subsidiary, in May 1999, in order to change its state of incorporation to Delaware. In September 2001, Ampersand acquired 100% of the outstanding stock of AccuMed International, Inc., by means of a merger of AccuMed into the wholly-owned subsidiary. Shortly after the AccuMed merger, we changed our name to Molecular Diagnostics, Inc. Subsequently, in June 2006, we changed our name to CytoCore, Inc.
 
On January 11, 2014, MEDITE Cancer Diagnostics, Inc. (formerly CytoCore Inc. the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with MEDITE Enterprises, Inc., a Florida corporation (“MEDITE”), MEDITE GmbH, a corporation organized under the laws of Germany and wholly owned by MEDITE (the “Subsidiary”), Michael Ott and Michaela Ott, the sole shareholders of the MEDITE at that time (collectively, the “Shareholders”).
 
Pursuant to the Purchase Agreement, the Company agreed to acquire 100% of the issued and outstanding capital stock of MEDITE from the Shareholders in exchange for the issuance of up to 15,000,000 shares of the Company’s common stock (the “Shares”) to the Shareholders. The Purchase Agreement also provides that the Shareholders will indemnify the Company for certain losses during the one-year period following the “Closing” as defined in the Purchase Agreement. In connection with such indemnification rights, the Purchase Agreement provided that 3,750,000 of the Shares was deposited with the Company and held for a period of 12 months to cover certain indemnification claims that the Company may have against the Shareholders.  These shares were released to the Shareholders during 2015.
 
Closing of the acquisition of MEDITE was conditioned upon: (i) the completion of a private placement transaction resulting in gross cash proceeds to the Company of $1.25 million (the “Private Placement”), and (ii) the conversion of certain accrued wages of the Company into shares of the Company’s common stock. In addition, as of the Closing, there was to be no more than 18,750,000 shares of the Company’s common stock exclusive of any shares of the Company’s common stock issued in connection with the Private Placement.
 
On April 3, 2014, pursuant to the terms and conditions of the Purchase Agreement, as amended to date, the Company acquired 100% of the issued and outstanding capital stock of MEDITE in exchange for the issuance of up to 15,000,000 shares of the Company’s common stock to the Shareholders, of which 14,687,500 shares were issued upon the Closing of the Acquisition. In the event that the Company issued less than $2,500,000 at a price of $1.60 in the Private Placement, the Company was required to issue an additional 312,500 shares of common stock to the Shareholders. The Company issued these shares during 2015. Also during 2014, prior to the reverse merger, the Company issued 697,234 shares of common stock for payment of certain accrued wages of the Company.
 
Recent Developments
 
In January, 2018 the Company raised $150,000 in additional capital under the same terms as described in the Subordinate Convertible Notes see Note 6. 
 
Also in January, 2018 the Company received a term sheet for additional debt financing, consisting of a convertible note with an initial conversion price of $0.075 per share.  Each $0.075 invested also receives one Common Stock share.  The Convertible Notes are subordinate to the GBP debt described in the GPB Debt Holdings II, LLC (“GPB”) Convertible Notes Payable see Note 6, have a 5-year maturity date and bear a 12% annual interest rate, payable semi-annually.  The Company received $1,955,000 in capital and issued 26,066,667 common stock shares under these terms as of May 17, 2018.
 
 
 
On October 16, 2016 the Company filed a Form D to issue up to $6.9 million of convertible secured promissory notes and approximately 5.3 million warrants to issue common stock at $0.60 a share.
 
 On October 26, 2016, the board of directors appointed David E. Patterson to the position of Chief Executive Officer and Director of the Company. Pursuant to Mr. Patterson’s executive employment agreement with the Company, the commencement date of Mr. Patterson’s appointment was October 31, 2016. He was granted 250,000 restricted shares of the Company’s common stock (the “Shares”). The Company valued the Shares at $0.50 per share, based on the fair value of the stock on the date of grant. On November 5, 2017, the Board of Directors (the “Board”) of the Company held a meeting whereby David E. Patterson informed the Board of his decision to retire as Chief Executive Officer of the Company and resign his position as Chairman of the Board and Board member of the Company, all effective immediately.  The Board approved a Transition Agreement whereby Mr. Patterson would receive three equal monthly payments with each payment being equal to his monthly salary, and all future restricted stock grants in the amount of 166,667 shares pursuant to his employment agreement would fully vest as of January 1, 2018 and be issued in consideration for assisting the Company through a transition period. Mr. Patterson rescinded those shares in March 2018.
 
Thereafter, the Board, by unanimous consent, appointed current Board member, William Austin Lewis IV, to the position of Chairman of the Board of Directors of Company to serve until such time as his removal or resignation.
 
Also, Stephen Von Rump was appointed by a unanimous vote of the Board to the position of Chief Executive Officer of the Company upon the same terms and conditions as his current employment, to serve until his resignation or removal.
 
On November 12, 2017, the Board of Directors of the Company held a meeting whereby they appointed Joel Kanter, age 61, to the position of Director to serve until such time as his resignation or termination. Mr. Kanter’s appointment fills the vacancy created by the resignation of David E. Patterson.
 
On January 2, 2018, the Board accepted Susan Weisman’s resignation as Chief Financial Officer.  Ms. Weisman received a lump sum payment in consideration for assisting the Company through a transition period ending on January 31, 2018.
 
The Company filed a Form D on March 7, 2017, initiating a total offering of $4,250,000, of which $25,000 in stock subscription were received by the Company as of December 31, 2017, representing the purchase of 50,000 shares of common stock.
 
During the year ended December 31, 2017, the Company issued 5,060,000 shares of common stock for $2,530,000, less $187,000 of issuance costs. In connection with the issuance of common stock, the Company issued 2,530,000 warrants to purchase shares of common stock at $0.50, for a term of 5 years. We also issued 50,000 shares from stock subscriptions of $25,000 at December 31, 2016 and issued 25,000 warrants on the same terms and conditions.
 
 Information about Industry Segments
 
The Company operates in the industry segment for cancer diagnostics instruments and consumables for histology and cytology laboratories.
 
Definition:
Histology - Cancer diagnostics based on the structures of cells in tissues
Cytology - Cancer diagnostics based on the structures of individual cells
 
Cancers and precancerous conditions are defined in terms of structural abnormalities in cells. For this reason, cytology is widely used for the detection of such conditions while histology is typically used for the confirmation, identification and characterization of the cellular abnormalities detected by cytology. Other diagnostics methods such as marker-based assays provide additional information that can supplement, but which cannot replace cytology and histology. The trend towards more personalized treatment of cancer increases the need for cytology, histology and assays for identifying and testing the best treatment alternatives. We believe that this segment will therefore be increasingly important for future development of strategies to fight the “cancer epidemic” (World Health Organization: World Cancer Report 2014) which expects about a 50 % increase in cancer cases worldwide within the next 20 years.
 
 
 
This segment sees a trend toward, and demand for, higher automation for more throughput in bigger laboratories, process standardization, digitalization of cell and tissue slides, and computer aided diagnostic systems, and in general a search for more cost-effective solutions.
 
MEDITE acts as a one-stop-shop for histology (also known as anatomic pathology) laboratories either as part of a hospital, as part of a chain of laboratories or individually. It is one out of only four companies offering all equipment and consumables for these laboratories worldwide. The MEDITE brand stands for innovative and high-quality products – most equipment is made in Germany – and competitive pricing.
  
For the cytology market, MEDITE offers a wide range of consumable products and equipment; in particular for liquid-based-cytology which is an important tool in cancer screening and detection in the field of cervical, bladder, breast, lung and other cancer types. It also developed an innovative, easy to use standardized staining solutions, and a very innovative and effective early cancer detection marker-based assays. These new developments are cost effective solutions able to replace more expensive competitive products, and therefore are also becoming the first choice for the growing demand in emerging countries.
 
All of the Company’s operations during the reporting period were conducted and managed within this segment, with the management team reporting directly to our Chief Executive Officer. Further during the 2017 period we added key personnel with excellent historical performance in new product commercialization, sales development and internal operations improvement. For information on revenues, profit or loss and total assets, among other financial data, attributable to our operations, see the consolidated financial statements included herein.
 
Description of Business
               
MEDITE manufactures, develops, markets and sells a wide range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. Most devices are manufactured at its German facility, and most consumables are staged for export there. This facility also acts as central location managing all international sales and logistics outside of the Americas. A direct sales force is employed in Germany and the U.S, and over 80 more countries worldwide are covered with an existing and continuously expanding network of independent distributors. In the U.S. MEDITE has established sales and distribution channels that will prioritize its products.
 
A general goal of MEDITE in sales is to act as a one- stop-shop for its customers. Instrument purchases are usually bigger investments, with prices sometimes above the $50,000 level, which are more seasonal and depend significantly on investment budgets. Therefore, MEDITE also offers to sell the day to day consumables and sees its brand not just on the devices, but also on the supply products.
 
The U.S. headquarters in Orlando, Florida manages the Company worldwide and is developing, establishing and realizing the strategic goals of the Company. It also acts as distributor for the Americas, maintaining a warehouse with instruments, repair parts and consumables available for sale and for warranty obligations to its customers, and taking care of centralized marketing, regulatory issues and finance. A second location in the U.S. operates as our research laboratory for cancer assays and other cytology developments and is located in the Chicago area.  
 
For sales, MEDITE targets three major areas; U.S., Europe and China, and now increasingly Eastern Europe and North Africa. While the U.S. is currently the largest potential market for MEDITE products, it is expected that the rest-of-world will experience continued growth through 2018 due to the more established presence of MEDITE in those markets.
 
Currently, MEDITE’s principal customers are histology and cytology laboratories associated with hospitals or research institutions and independent laboratories in markets with direct sales and distributors in markets covered by them. In the U.S. market, MEDITE executed several distribution contracts with third party sales organizations additional to its direct sales. 
 
For manufacturing of its high-quality devices at the German facility, an enterprise resource planning software is used to manage the material flow and production planning for about 6,000 different parts. Management has evaluated and is in the process finalizing its review of a company-wide system anticipated to be implemented by the late 2018. Due to the wide range of products, the availability of all parts is essential to finish a manufactured product within an acceptable lead time. Smaller equipment items and all consumable products have to be available at any time to guarantee the customer continues to work. Usually orders of these goods are shipped within 24 hours after receiving the order, while for own-manufactured equipment, the delivery times is between 4 to 8weeks. This is not acceptable to many customers and the Company continues to implement production planning processes to improve delivery time. A major change in 2018 is that the Company now plans and builds to forecast, whereas it previously built mostly to confirmed orders (backlog).
 
 
 
The Company’s strategy is to use its pipeline of newly developed and currently under development of innovative devices, consumables and newly developed assays to set new standards in the industry, create new markets and to take over additional market shares from its competition. These new offerings will further allow MEDITE to develop significant strategic relationships to enhance sales and revenue growth.
 
Products
 
Histology
 
MEDITE offers its customers a comprehensive range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. Most important to this segment are very high levels of reliability, efficiency, and safety.
 
Starting from receiving the biopsies, it may be necessary to decalcify them; for example, from bone tissue. The USE 33 is an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures.  Due to this innovative technology it can increase the speed of decalcification by 300% compared to just using acid.  Instead of days or even weeks, the biopsies are ready much earlier for further processing, which shortens the patient’s diagnosis wait time. This specific instrument also is often used in research labs.
 
The next step is the tissue processing (dehydration and fixation), which usually runs automatically in the laboratory overnight with no human supervision. MEDITE’s TPC 15 Duo and Trio instruments offer a very high capacity of 440 or 660 biopsies per run and also offer two or three independent protocols. Therefore, depending on the size and kind of tissue, it can process simultaneously the different steps, and therefore replace two or three instruments of similar competitor’s instruments. It also offers a very high level of safety. In the unlikely situation of an error or just a power outage, it has a back-up battery, and the emergency mode puts the biopsies into a safe position. An advantage of this kind if tissue processer is the usability with Xylene replacements like Isopropanol, a second-grade alcohol The European Unit is proposing to ban Xylene in laboratories and so the TPC15 is the perfect unit to do so. Competitor systems with pumps have a higher risk in using Isopropanol. The price of the unit is very competitive in its market based on its high capacity.
 
After tissue processing, the tissue will be transferred into a paraffin block using an embedding center. MEDITE was the original inventor of the three-piece units (heating, dispensing, and cooling). It is much more flexible to adapt to human and laboratory needs. While the dispensing unit usually is in the center, the others can be added to the right or left depending if right or left handed. Additional cooling units can also be added to extend the capacity. MEDITE offer two types: the low-cost set TES 99 when budget matters, and the high-end version TES Valida when design and technology is more important. The TES Valida is recognized as the best system currently available worldwide. Every histology lab has at least one system, but usually two or more of these embedding centers in place – historically the market consists of sales of several thousand units each year.
 
With the paraffin block from the embedding center, the biopsy needs to be sectioned using a microtome. Several types of automation are demanded by the market; on the low end a manual microtome, in the middle a semi-automatic version, and on the high end, a fully automatic microtome. For a microtome, the most critical functionality is extremely precise mechanics able to cut slices of as small as 1 microns in thickness. Five years ago, MEDITE developed the semi-automatic version M530 first, then the fully automatic version A550 and started in 2014 the development of the manual version M380 – mainly for the Chinese market – of which the first production of these units was sold in August 2015. Since 2016, the microtomy manufacturing has operated in a second German facility in Nussloch where the roots of worldwide microtomy started with skilled employees. Since the new versions of all three types of microtomes have been brought to the market with growing success. For China, a special type of manual microtome M380 was developed to match the unique usage characteristics of histotechnologists there. As part of tissue sectioning, a freezing microtome called a “cryostat” can be used for fast biopsies when a patient needs a diagnosis immediately e.g. still being in the operational theater. Prototypes of the M630 were tested in the field in 2017 and manufacturing of the first set of this instrument will start in 2Q 2018. Based on the forecast with direct and incremental sales we expect to sell 75 units within the first year. The Company’s strategic goal for the cryostat is to offer a high-quality device for a competitive price to win 10% of the market (750 units annually).
 
When the sections of the tissue are transferred to a microscopy slide they undergo a staining process with several different protocols depending on the type of tissue. To manage high volumes, robotic multi-staining systems are used. MEDITE offers the most flexible system, TST 44, which is computer controlled and can run several staining protocols simultaneously, and its unique feature software can even overtake slower with faster protocols. The maximum capacity is about 400 slides per hour with that system. This robotic stainer is currently going through an update and modernization project during 2018. This includes the latest innovative technology software, new color touch screen, new X-Y-Z robotic technology and a modern newly designed case. For higher volume throughput, e.g. for cytology laboratories, MEDITE offers the COT 20 linear staining system using a kind of conveyor technology to realize a capacity of over 1,000 slides per hour.
 
 
 
The final step to the process is to place a cover over the tissue on the stained microscope slide to preserve it for many years and make it ready for digital scanning or directly for diagnoses under the microscope by a pathologist. MEDITE offers the RCM 9000, the latest version of a stand-alone robotic coverslipper using glass coverslips. Another option MEDITE developed is the ACS 720 glass coverslipper which is connected directly to the TST 44 multi-stainer creating a higher level of automation by bridging the former manual step between two separate instruments. This instrument combination – known in the industry as a “combi” - is very competitive and more and more public tenders are asking for it. Finally, to also support higher throughput laboratories, MEDITE developed the robotic coverslipper TWISTER using a clear film instead of cover glass. This triples the capacity of a glass coverslipper up to 1,200 slides per hour.
 
Several smaller devices for stretching, drying, cooling, exhausting, recycling, printing etc. are also manufactured by MEDITE but not specifically described herein. These products are usually competing mainly on price, but quality is still important.
 
In the segment of histology consumables, MEDITE offers everything necessary to run its instruments and to run the complete histology laboratory. This includes embedding cassettes, microscope slides, paraffin, staining solutions, reagents and other products. Some of the consumable products are MEDITE developments and exclusively manufactured by or for it. Other products are MEDITE branded but manufactured and delivered from external high-quality vendors. The procurement focus therefore is on high quality, not lowest price.
Cytology
 
The product strategy of MEDITE in this market is to offer products for the whole process, from cell collection through processing to diagnosis.
 
Some of the histology processing instruments of MEDITE are also used in cytology labs, like the staining and coverslipping systems.  Characteristics of the sample collected determine the quality of the results of any tests performed on the sample. The sensitivity and/or accuracy of a test is, for example, likely to be reduced if the sample collection device or method does not capture a sufficient amount of the target analyte, alters the analyte of interest, or collects significant quantities of substances that interfere with the analysis. One of the Company’s major areas for product development is in sample collection for specific cells and tissues.
  
Cervical cytology specimens have traditionally been prepared as “smears” where the cells on the collecting device are literally wiped or smeared onto a microscope slide. In the 1980s, an alternative method, variously called a “monolayer” or “liquid-based” preparation (“LBP”), was introduced. In this method, cells are washed off of the collection device into a preservative solution to form a cell suspension. A portion of this cell suspension is then transferred to a microscope slide. LBPs presently account for about 80% of the cervical cytology slides prepared in the U.S., but despite the technical benefits of LBPs, only about 20% of the cervical cytology slides in the European Union and much lower percentages in the rest of the world are prepared in this manner. The primary limitations to greater adoption of LBPs outside of the U.S. are the high equipment and ancillary supply costs associated with the two predominant LBP methods. With the acquisition of MEDITE, the Company sells two alternative LBP methods product lines, the SureThin line which is competing against the market leader Hologic, and the SafePrep line which is competing against the second largest market player Becton-Dickinson. Both product lines cover the complete set of consumables necessary to preserve, extract and process cells onto a microscopic slide. For the SureThin line, MEDITE also offers a processing device automatically extracting the cells from the preservative vial and transferring it on the slide. Both systems have a significantly lower price than the competition, which is increasingly important for some markets like the US, where a cytology laboratory needs to lower its cost due to lower reimbursement rates. This lower price level itself also creates new markets, where it is now more affordable even to smaller laboratories and can better compete against the traditional Pap smear. Once a cytology specimen has been deposited onto a microscope slide, it is stained in order to assist the cytologist in detecting and identifying the various features of the deposited cells that are relevant to determining whether the cells are normal, dysplastic or cancerous.
 
 
 
The Company is also now developing a new suite of products called SureCyte as part of its digital pathology strategy, including a new stain called C1 for use in many cytology and histology screening and diagnostic applications. The new morphology stain is intended for use as a direct replacement for the Pap and H&E stains used in most cytological and histological tests. It will initially be introduced for use in tests where the specimens are evaluated visually with formulations for use with our automated slide imaging and analysis system and possibly also flow cytometer systems to follow.  
 
As mentioned above, we are developing a family of immunocytological assays that combine the measurement of bio molecular cancer markers and cell morphology in a single test. These assays are intended to detect the presence of specific proteins and other markers that are indicative of the presence of a target disease, allow characterization of abnormal cells, or provide an estimate of the risk of disease progression. These assays are specifically designed to be compatible with the C1 stain and may be evaluated using our automated slide imaging and analysis system. An added benefit of C1 is that after the specimen has been evaluated, it can be counterstained with a Pap or other conventional stain for manual confirmation or archiving. Internal laboratory tests show a very high level of specificity and sensitivity, and the Company currently is preparing a strategy for the clinical evaluation. A system like this has the potential to displace the current expensive HPV testing methods by offering a significantly higher specificity and sensitivity, which management believes offers a significant market opportunity.
 
 Over the last few years, the MEDITE developed software for an imaging system for computer aided diagnosis of slides including its new C1 stain and its revolutionary new biomarker-based SureCyte assays. The intent of a medical screening system like this is to differentiate between patients who show no evidence of the target disease state (“normal”) and those who do (“abnormal”). Patients who have abnormal screening results are offered follow-up testing to confirm, diagnose, classify and determine the extent of disease and, where appropriate, determine the appropriate treatment. Patients who have a normal screening result are not offered these services. To allow scarce medical resources to be focused upon those patients having the greatest need, screening programs are structured to differentiate between normal and abnormal patients as accurately, rapidly, reliably and cost effectively as possible.
 
The Company also is looking at new ways to analyze the SureCyte data, for example ploidy analysis (popular in China) and micronuclei counting. These have both been touted as alternatives to regular PAP analysis.
 
The new C1 stain is also expected to work in Non-GYN applications (e.g. lung, bladder, thyroid and other cancers) and for Non-GYN imaging together with the SureThin consumables and processing units.
 
The Company is also developing a new sample self-collection product called SoftKit, which is a low-cost disposable device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. The Company has filed and issued patents in multiple countries.   The Company plans to finish the final design of SoftKit in 2018, which can be used for the collection of cellular samples that can potentially be screened for a variety of gynecological cancers (including cervical, endometrial, and ovarian), and for the collection of gynecological samples to be tested for the presence of HPV and variety of gynecological cancers and additional indications such as sexually transmitted disease (“STD”) testing. SoftKit addresses several market niches and segments that are not supported effectively by traditional gynecological sampling devices. SoftKit is designed to eliminate the need for assistance from a medical professional when collecting gynecological samples for many screening applications. The Company believes that this feature, in addition to the range of tests that can be performed on a SoftKit sample and SoftKit’s low cost, make it particularly attractive for use in large scale public health screening programs.
 
Product Development and Research
 
With the acquisition of MEDITE, the Company currently employs 11 full-time equivalents for software, electrical and mechanical design engineers. The strategic goal is to optimize development processes to shorten the development period and time to market for several ongoing and new R&D projects.
 
MEDITE’s product development department is including engineering skills and technology in software development, multilayer circuit board design, electrical design, 3-D product design in (using CREO design software), technical regulatory documentation, often individually for different countries worldwide, and quality management based on its ISO 9001 certificate.
 
The main focus of the development team during 2017 was working on innovative and new products like the cryostat M630 and the film coverslipper TWISTER, a cytology processor and several updates and modernization projects for existing instruments.
 
In addition, a team of experienced researchers in biochemistry, with successful track records and a very high reputation in that segment, are working on special stains and assays for detection of pre-cancerous and cancerous conditions in cytology and histology. Some of these developed products are currently undergoing the commercialization process, starting with field studies and are expected to be rolled out in the near term.
  
 
 
Markets and Marketing Objectives
 
As described also in other paragraphs of this report, our target is basically the worldwide cancer diagnostics market. Currently we serve in particular the histology and cytology segments of this total market, but we are open to entering other cancer diagnostics segments in the future when attractive economically. The total annual market volume of histology and cytology is approximately $5.8 billion with annual growth rates between 10 and 30% depending on the specific market, cancer segment and country. 
 
Cancer is a major threat for mankind and the recently published “World Cancer Report 2014” by the World Health Organization, states that the number of cases will increase world-wide by about 57% to 22 million cases in the next two decades. At the same time cancer deaths will rise from 8.2 million to 13 million per year.
 
MEDITE’s current and future products will assist in the detection of precancerous and cancerous conditions and provide the basis for more efficient and cost-effective diagnosis.  The net effect of utilizing MEDITE’s anatomic pathology (tissue based) and cytology (cell based) products may result in more lives saved at lower costs.
 
While distributing currently into approximately 80 countries of the world, the Company’s sales and marketing efforts are in particular focused on the three major markets of U.S., China and Europe.
 
Currently the target groups are the histology and cytology laboratories as end users. In Germany and (in some cases) the U.S. it sells directly to these laboratories, while in other countries it sells indirectly to them through its international network of distributors. Several of the products currently being developed by the Company may also be sold to national health programs and/or non-governmental public health agencies, or possibly directly to consumers. The Company use several means like sales and technical training, advertising materials, special offers etc. to motivate its distributors selling MEDITE products. Depending on local markets, the contact to public health care organizations or other public authorities responsible for purchasing medical product is important. While in many markets the laboratories directly can decide about purchases, in others they have to undergo a tender process.
 
Worldwide, approximately 180 million Pap and 60 million breast cancer screening tests are performed annually. The potential market is approximately 1.5 to 1.8 billion women for each of these tests. Bio-molecular screening, diagnostic, and treatment products consequently are being developed to detect disease states early, so they can be dealt with before they become life threatening and expensive to treat. The Company is designing and developing products to satisfy this paradigm shift and focus more on diagnostic methods and tools for early detection.
 With the new products currently in the late stages of their development and/or regulatory processes, like the SureThin US gynecological (gyn) application or the SoftKit, the Company is targeting different groups of end-users and establishing the logistics needed to reach and support these users. Similarly, in addition to marketing to laboratories, the SoftKit is expected to be marketed to public health agencies as well as being directly marketed to the patient to motivate them to purchase it on the internet, a pharmacy or similar facility. MEDITE will continue to adjust its marketing to the specific needs of each product group.
 
For the cytology and histology laboratories, the Company distributes national or international product catalogs each year with a wide overview of the related product lines. These are available in English, German and Polish languages and offered as export catalogs to its international distributors who translate them into the appropriate local languages. The catalogs are sent directly to the laboratories where MEDITE is selling directly. The Company has their products also featured on their websites for sales and distribution of information.
 
MEDITE also attends several local, national and international exhibition and congresses which are segment-specific or medical product-orientated like the NSH in the U.S., the ECP in Europe, the Arab Health exhibition in Dubai, the Medica exhibition in Germany and many more. 
 
Sales and Distribution
 
The Company is distributing its products to over 80 countries worldwide while focusing on the three major areas of U.S., Europe and China.
 
Depending on their experience, strength in their local market and potential sales volume, MEDITE uses exclusive or non-exclusive distribution national contracts. Due to the fact that three of the major competitors, Leica, Thermo and Sakura are changing their distribution strategy more towards direct sales, several well-established independent distributors with both international and national sales coverage have shown increased interest to sell MEDITE products as a priority offering versus other products lines.
 
 
 
MEDITE in the U.S. has deepened selling and marketing relationships with two major marketing leaders with national distribution channels. One of the companies is a publicly traded international firm with a market cap of several billion. MEDITE is their chosen provider of Histology and Cytology solutions. While until now the Company has not realized the full potential of this distribution channel, it is working to gain its share of this market. A second distribution channel in the U.S. is selling MEDITE products through other established sales organizations, utilizing their sales agreements with end users and through their sales representative network. This network is considered an important part of MEDITE’s future sales growth strategy. These various distribution channels are managed by senior experienced sales directors to insure planning and penetration. MEDITE will also use a direct sales approach for certain large customers, using employed product specialist e.g. in cytology or even using our service employees for technical assistance, training, installation and sales. The channel of directs sales will be increased in the future using the Company’s own employees or sales representatives.
 
In Europe, the Company sells direct in Germany with employed regional sales representatives and through a network of independent distributors in all other countries. Some of its sales partners have worked with MEDITE for more than a decade. MEDITE schedules several dates for sales training of distributors and technical training for their technical service employees for free each year to keep a high level of experienced staff trained for MEDITE products worldwide, and also to collect feedback for product improvement and development.
 
For the Chinese market, MEDITE uses a strategic distribution agreement with its local partner UNIC Medical. The major shareholder and president is a professor of pathology and has established a wide network of sales teams in China and other Asian countries. With their help, the brand name MEDITE has attained recognition second in its segment. MEDITE together with UNIC successfully got Chinese FDA approval for all MEDITE histology instruments in 2014 and for the cytology instrument late in 2015. Since then the UNIC team has been increasingly successful is selling MEDITE products in China. The shared goal in China is to become the market leader in the histology and cytology market.
 
The rest of the world is supported by an experienced team of export professionals at the German facility also acting as the Company’s logistic center. Especially in the medical area, a deep knowledge of custom tariffs and rules, international regulatory restrictions, international payment terms and dangerous goods shipment regulations, are major skills needed by these employees.
 
Government Regulation, Clinical Studies and Regulatory Strategy
 
The development, manufacture, sale, and distribution of medical devices are subject to extensive governmental regulation worldwide. In the U.S., our products are regulated under the Medical Device Amendments to the Food, Drug and Cosmetic Act (the “FD&C Act”) and cannot be sold, shipped or promoted in interstate commerce without prior “clearance” or “approval” by the FDA. In the European Union (“EU”), medical devices are regulated under the Medical Device, In-Vitro Device and other Directives that require that each product be CE Marked to show that it conforms to all of the requirements of the applicable Directive(s) before it can be imported into or sold in the EU. MEDITE products which are selling in the U.S. are FDA registered and all have the CE mark.     
 
The regulatory systems in other major markets such as China and South America continue to undergo substantial changes and now in many respects resemble the systems in the EU. The CE Mark is now accepted or required in essentially all significant markets other than the U.S. In addition to having to obtain the appropriate regulatory approvals, we are also required to register our products with the national health authority in many countries in which we expect to do business; we may have our quality and manufacturing systems inspected and/or audited by representatives of various national authorities; and may have to conform to additional regulations imposed by individual countries.
 
Under these regulations, we are subject to certain registration, record-keeping and reporting requirements. Our manufacturing facilities and those of our strategic partners, may be obligated to conform to specified quality standards, and are subject to audits and inspections.   We are also subject to national, state and local laws relating to such matters as safe working conditions, manufacturing practices and environmental protection.   Failure to comply with these regulations could have a material adverse effect on our future operations and may impose additional costs and risks.
 
In the U.S., the FD&C Act generally bars selling, advertising, promoting, or other marketing of medical devices that have not been authorized (approved or cleared) by the FDA. The promotion or sale of medical devices for non-approved or “off-label” uses is prohibited.   The FDA also regulates the design and manufacture of medical devices. These regulations have been largely, but not completely, harmonized with the ISO quality system standards for medical devices that are used for similar purposes in most other countries.   This incomplete harmonization requires us to maintain two separate, but equal quality systems and increases the cost and complexity of regulatory compliance.   The FDA and the corresponding regulatory agencies in other countries may withdraw product clearances or approvals for failure to comply with these regulatory standards and may impose additional sanctions.
 
 
 
-10-
 
In the U.S. most low to moderate risk medical devices that have legally marketed predicates receive “clearance” to market through a process described in Section 510(k) of the FD&C Act. In order to receive clearance under the 510(k) process a product must be shown to be “substantially equivalent” to an appropriate legally marketed “predicate device”. High risk devices and devices that do not have a predicate require “approval” via a Pre-Market Approval (“PMA”) submission in which de-novo demonstration of the safety and efficacy must be established.   Changes to a product, its intended use, and/or its labeling often require the submission of another 510(k) or PMA application.   Obtaining approval to market via the PMA process takes substantially longer and is far more expensive than obtaining clearance to market via the 510(k) notification process.
 
Each country has historically imposed its own unique regulations on medical products. In recent years, however, there has been a trend toward the harmonization of these regulations resulting in greater consistency between countries. This has resulted in a large and growing number of countries (over 70 as of this writing) adopting the CE Mark as a central element of their regulatory process for medical devices. The U.S. is the only major country that has not adopted the CE Mark. For a product to be CE Marked, the manufacturer must demonstrate to the satisfaction of the regulatory authorities that the product is safe and effective (conforms to the “Essential Requirements” for that class of product) and that it is manufactured in accordance with specified quality standards.   In most countries the CE Mark is a pre-condition for medical device registration and in some places such as the EU, is mandatory in order for a product to be imported into or sold within the country or region.   Failure to comply with the regulations pertaining to CE Marking can result in product seizures and other sanctions.  
 
Although Company registration to the ISO 13485 quality system standard is not required for companies selling Class I (lowest risk category) medical devices and products in the EU, such registration is for all practical purposes mandatory for companies selling products in Class II and higher. All products that are presently being sold and a significant portion of those that are in development are currently classified as Class I devices. However, some of our upcoming products are expected to be in Class II or Class IIa and some changes that are being discussed in the EU may, if they come to pass, result in the reclassification of some of our Class I products into Class II. Our quality system is presently registered to ISO 9001 which is the parent standard of ISO 13485. We presently plan to have our quality system registered to ISO 13485 by the end of 2018.
 
The EU is in the process of determining whether the various Directives pertaining to medical devices should be “recast” to bring them into conformance with the recommendations of the Global Harmonization Taskforce (GHTF) and is also studying the possibility of replacing these Directives, which must be transposed into national laws by each country in order to become effective, with EU-wide laws that do not require transposition. Conversion from the present Directives to corresponding EU laws could be beneficial in that it is expected to eliminate country-specific differences in how the Directives are applied and enforced and therefore facilitate our compliance with the pertinent regulations in the EU.    Harmonization of the current medical device classification system with that recommended by the GHTF may, however, result in some or all of our products being placed in more restrictive categories that could significantly increase our regulatory compliance costs and time to market.
 
The GHTF, which is comprised of representatives from major medical device regulatory agencies such as the FDA, has developed a single unified medical device identification system that will be mandatory as it is implemented worldwide.   These regulations went into effect in many countries during 2014 and went into effect in additional countries by the end of 2016 with a final implementation in 2020. The Company is positioned to comply with these new regulations under this regulation for our current products and have the mechanisms in place to obtain such codes and the registrations of the affected products, if needed, in the future. In a number of countries these regulations include user fees that will increase our cost of regulatory compliance.
 
We are also required to comply with certain environmental regulations with respect to products that are sold in various countries. One of these regulations is the Directive on Packaging and Packaging Wastes in the EU that: mandates the minimization of packaging; restricts the use of certain packaging materials; and imposes requirements, including possible “take-back” provisions, with respect to the recycling of packaging materials. All of our current products comply with the requirements of this Directive.   At present, we comply with the recycling portions of this Directive by ensuring that all packaging materials are compatible with recycling programs that are in place in the EU.   However, in the future we may be required to take a more active role in the recycling of certain types of products including possibly “taking back” and recycling laboratory instruments. Implementing a compliant take-back program will increase our operating and regulatory compliance costs.
 
 
 
-11-
 
In the EU electronic products, including clinical laboratory instruments are required to comply with two environmental Directives, one of which requires that the manufacturer “take back” and recycle the electronic portions of these instruments and the other (the so-called RoHS Directive) of which restricts the presence of certain materials in electronic products. The Company complies with the RoHS Directive by requiring its suppliers to use only RoHS complaint materials in the construction of its products.
 
The “REACH” regulation, which requires the registration of all chemical products produced in or imported into the EU is presently in its implementation phase. The long-term impact of this extremely complex multi-level regulation on the Company is unknown at present but is anticipated to be minimal in the near term as our sales of chemical products (stains, preservative, etc.) are and are expected to continue to be at less than the threshold levels for registration and reporting. An increase in sales of such products above currently forecast levels and/or a reduction in the applicable thresholds could potentially result in additional costs to the Company.
 
Data from clinical trials and studies is often required in regulatory submissions and is highly desirable for use in product marketing activities. In general, at least one trial or study is necessary for each new product and additional studies or trials are needed to support new or modified indications for use and new marketing claims.  
 
Cost and Reimbursement
 
In the U.S., laboratory customers bill most insurers (including Medicare) for screening and diagnostic tests such as the Pap test. Insurers, such a private healthcare insurance or managed care payers, in addition to Medicare, reimburse for the testing, with a majority of these insurers using the annually-set Medicare reimbursement amounts as a benchmark in setting their reimbursement policies and rates. Other private payers do not follow the Medicare rates and may reimburse for only a portion of the testing or not at all. 
 
Outside of the U.S., healthcare providers and/or facilities are generally reimbursed through numerous payment systems designed by governmental agencies, such as the National Health Service in the United Kingdom, the Servicio Sanitaris Nazionale in Italy and the Spanish National Health System, as well as private insurance companies and managed care programs. The manner and level of reimbursement will depend on the procedures performed, the final diagnosis, the devices and/or drugs utilized, or any combination of these factors, with coverage and payment levels determined at the payer’s discretion.  
 
Our ability to successfully commercialize the current and future products depends in part on the extent to which coverage and reimbursement for such products will be available from third-party payers in the U.S. such as Medicare, Medicaid, health maintenance organizations and health insurers, and other public and private payers in foreign jurisdictions. The coverage policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities regarding which medical products they purchase and the prices they are willing to pay for those products. In some countries, our ability to commercialize products will also depend upon us becoming a qualified bidder on the tender offers issued by the National Healthcare Authority. When we succeed in bringing products to the market, we cannot be assured that third-party payers will pay for such products or establish and maintain price levels sufficient for realization of an appropriate return on our investment in product development. Additionally, we expect many payers to continue to explore cost-containment strategies (e.g., competitive bidding for clinical laboratory services within the Medicare program, so-called “pay-for-performance” programs implemented by various public and private payers, etc.) that could potentially impact coverage and/or payment levels for current or future MEDITE products.  
  
Competition
 
Historically, competition in the healthcare industry has been characterized by the search for technological innovations and efforts to market such innovations. Technological advances have accelerated the pace of change in recent years. The cost of healthcare delivery has always been a significant factor in markets outside of the U.S. In recent years, the U.S. market has also become much more cost conscious. The Company believes technological innovations incorporated into certain of its products offer cost-effective benefits that address this particular market opportunity.
 
MEDITE is currently focused upon histology and cytology which are the two major fields of the anatomic pathology market. Each of these segments is dominated by only 2 – 3 major players. In histology, the Company’s manufactured instrument line competes with those from Leica, Sakura and Thermo Fisher, while in cytology its current SureThin and SafePrep product lines compete with products from the Cytyc division of Hologic and the TriPath division of Becton-Dickinson. Unlike certain of these competitors, MEDITE is a global one-stop supplier for all histology and cytology laboratories.
  
 
 
-12-
 
In cytology, the Company is currently developing a versatile fully-automated, objective analysis, screening and evaluation system for cancer screening that can be used with its current liquid-based cytology SureThin line and the former CytoCore developed SureCyte stain, which is highly reproducible and produces staining results within seconds. This same system can be used with the Company’s newly-developed SureCyte biomarker assays and, unlike the few competing systems, it is specifically designed to perform cytological screening for a broad range of cancers when equipped with the appropriate software and reagent modules.
  
In general, the Company believes that its products compete on a combination of clinical performance, accuracy, functionality, reliability, quality, product features and effectiveness in standard medical applications while being sufficiently versatile to support future applications. It also believes that cost control and cost effectiveness are additional key factors in achieving and maintaining a competitive advantage. It focuses a significant amount of its product development efforts on producing systems and tests that will not add to overall healthcare cost.
 
Operations
 
The Company’s operations consist of sales and marketing, research and development (including information technology), technical service, accounting and administration and manufacturing. Its quality assurance manager is independent and authorized to act at his own discretion in the interest of patient safety.
 
MEDITE instruments and certain other products are manufactured in the Company’s factory in Burgdorf, Germany. Product manufacturing is monitored by TUV Sud for the UL (“Underwriter Laboratories”, US electrical standard testing) while its quality system is periodically audited by DQS. Small lot manufacturing with Kanban flow control and ERP management is used to ensure the timely delivery of smaller instruments while minimizing finished goods inventories. Larger instruments, most of which are customized to meet the unique requirements of their purchasers, are manufactured to order with a short turnaround. Extra safety stock is maintained for the few single source items that are used in its products, while qualified second sources are maintained for all other critical items. All incoming purchased goods intended for resale, whether or not under the MEDITE brand name, or for use in the manufacture of MEDITE products, are subject to intensive incoming inspection, and all finished MEDITE manufactured products receive intense final quality control testing including 24-48-hour burn-in, as appropriate, to the specific product before shipment. MEDITE additionally audits and monitors the quality systems of third party suppliers of MEDITE-branded consumables and supplies.
 
The sales and distribution department is organized into the two major departments of direct sales and export (distributors). For direct sales the goal for consumables and smaller instruments is to ship them within 24 hours after the receipt of the order. The export department is handling quotes, orders and shipments to almost every country worldwide. Every query should be answered within 24 hours. After receiving an order for larger equipment, the manufacturing department informs the export department of the expected shipping date. 
 
The MEDITE enterprise resource planning system is an integrated software that handles sales, material management and production planning. It is also automatically connected to the accounting system, transferring customer and supplier invoices, payments and the material consumption as a just in time controlling tool.  Management has evaluated and is in the process finalizing its review of a company-wide system anticipated to be implemented by the middle of 2018. 
 
Intellectual Property
 
The Company relies on a combination of patents, licenses, trade names, trademarks, know-how, proprietary technology, trade secrets and policies and procedures to protect our intellectual property. It considers such security and protection a very important aspect of the successful development and marketing of its products in the U.S., Germany, China and other foreign markets.
 
 
 
-13-
 
Patents, trademarks and copyrights are essential components in the protection of MEDITE’s intellectual property worldwide. As the Company manufactures and sells products globally, it has designed its intellectual property strategy to provide the necessary protection while containing and managing the associated costs. Two of the major components of this strategy are the filing of “provisional” patent applications in the US, and of filing utility patent applications under the Patent Cooperation Treaty (PCT) or similar entry points into national patent offices worldwide.
 
With the passage of the America Invents Act (AIA), the patent systems in all major countries now award patents on a “first-to-file” basis that places a premium upon filing one or more patent applications as soon as it is determined that an invention meets the minimum standards for patentability. This filing is in the form of a “utility” application that meets all of the requirements for examination by a patent office. The U.S. offers the opportunity to file “provisional” patent applications that, while not being in form for examination and not providing any formal rights or protections, is accepted by almost all countries as officially establishing the “priority” or invention date for utility applications that are derived from it within one year of the date of the filing of the provisional application. Provisional applications therefore provide a means of obtaining the earliest possible priority date while allowing time to refine and expand the scope of the invention and associated claims that are included in any resulting utility application. The Company’s practice is to convert each of its provisional patent applications into some number of utility patent applications within this 12-month period. In most cases each provisional application results in one utility filing. However, in some cases a single provisional application can generate two or more separate utility applications and/or multiple provisional applications can be consolidated into a single utility application. During the examination of a utility application, the examining patent office may require the Company to divide the application into two or more separate applications or it may file a continuation-in-part patent application that expands upon the technology disclosed in an earlier patent application and which has the potential of superseding or improving upon the disclosure of the earlier application. For these reasons, estimating the number of patents that are likely to be issued based upon the number of provisional and utility applications filed is difficult.
 
MEDITE routinely prepares and intends to continue to prepare additional patent applications for processes and inventions arising from its research and development process. The protections provided by a patent are determined by the claims that are allowed by the patent office that is processing the application. During the patent prosecution process it is not unusual for the claims made in the initial application to be modified or deleted or for new claims to be added to the application. For this reason, it is not possible to know the exact extent of protection provided by a patent until it is issued. Recent changes in US patent law, particularly conversion to a “first to file” system and introduction of a challenge period after a patent is granted may influence our IP strategy, especially as related to the filing of provisional applications. Several recent court decisions are also expected to influence these decisions.
   
The Company’s products are or may be sold worldwide under trademarks and copyrights that it considers to be important to its business. It owns the trademarks relevant to these products and may file additional U.S. and foreign trademark and copyright applications in the future.  
 
Future technology acquisition efforts will be focused toward those technologies that have strong patent or trade secret protection.
 
The Company cannot be sure that patents or trademarks issued, or which may be issued in the future will provide us with any significant competitive advantages. We cannot be sure any of our patent applications will be granted or that their validity or enforceability will not be successfully challenged. The cost of any patent-related litigation could be substantial even if we were to prevail. In addition, the Company cannot be sure that someone will not independently develop similar technologies or products, duplicate our technology or design around the patented aspects of our products. The protection provided by patents depends upon a variety of factors, which may severely limit the value of the patent protection, particularly in certain countries. We intend to protect much of our core technology as trade secrets, either because patent protection is not possible or, in management’s opinion, would be less effective than maintaining secrecy. However, the Company cannot be sure that our efforts to maintain secrecy will be successful or that third parties will not be able to develop the technology independently.
 
 
 
-14-
 
Research and Development Expenditures
 
The Company’s research and development efforts are focused on introducing new products as well as enhancing our existing product line. We utilize mainly in-house research and development personnel and, in some cases, external research and development services including collaboration with universities, medical centers and other entities are used if management identifies these relationships to be helpful and efficient. Our research and development activities are presently conducted in the U.S. and Germany.  Management believes research and development is critical to our success and business strategy. Research work in the U.S. in the area of chemical and biological components is expected to continue for the foreseeable future as we seek to refine the current process and add additional capabilities to our analysis procedures, including the detection of other forms of cancer and precursors to cancer. We anticipate the need to invest a substantial amount of capital, including the cost of clinical trials, required to complete current developments and bring it to market.
 
The continuing development of new and update existing technology and consumables for histology and cytology is necessary to further increase the Company’s competitiveness and management intends to spend a certain percentage of revenue on an on-going basis. With increased revenue, the percentage attributed to research and development is anticipated to decline, even with the expenditures increasing.
 
Components and Raw Materials
 
Many of the raw materials used in the Company’s products are readily available from multiple diversified sources. As these raw materials typically account for less than 10 % of the cost of the finished parts that go into the product, changes in prices for these materials will not have a significant influence on our manufacturing costs.
 
For paraffin the raw material is oil based and therefore the price fluctuates depending on the commodity markets. Management believes that the sales prices are adaptable and can be adjusted for significant swings in oil prices.
 
Some of the staining solutions reagents are dependent on specific chemicals where the price also fluctuates. The Company typically will negotiate a fixed price with our supplier for a term of one year to limit its exposure.
 
The availability of electronic and electrical parts for circuit board manufacturing is another challenge the Company closely monitors. The Company has negotiated with our critical parts suppliers to provide 12-month notice before discontinuing parts and, the Company if necessary, will place a last large order for sufficient number of these parts to support the continued manufacture and support of all MEDITE products that use the part for the anticipated life of the MEDITE product. In addition, it takes advantage of the extended availability programs that are offered by some manufacturers of electronic components and assemblies. The Company also attempts to transfer this discontinuation risk to our external circuit board module vendors, if possible.
 
Working Capital Practices
 
The Company raised additional cash of $2,105,000 from the sale of convertible debt subsequent to December 31, 2017, through the date of this filing, all raised by May 17, 2018. Working capital has improved by approximately the same amount as of the date of this filing.   
 
Management continues to expand its product offerings and has also expanded its sales and distribution channels during 2018.
 
At December 31, 2017, the Company’s cash and restricted cash balance was $490,025 and its operating losses for the year ended December 31, 2017 had used most of the Company’s liquid assets.
 
Accrued salaries, vacation and related expenses at December 31, 2017, includes amounts owed the former CFO Robert McCullough of approximately $1.1 million and amounts owed to both Michaela and Michael Ott totaling approximately $104,000.  Included in advances – related parties are amounts owed to the Company’s former CFO Robert McCullough of $50,000 on December 31, 2017 and amounts owed to Michaela Ott, stockholder and former CEO of the Company, of 16,000 Euros, ($19,160 as December 31, 2017) and 71,000 Euros ($85,022 as of December 31, 2017) related to two short term bridge loans. The Company has established a payment plan agreement with Michaela and Michael Ott. See further discussion regarding the legal proceedings with Robert McCullough.
 
 The Company’s security agreement (described in detail below) with its lender GPB Capital has provided borrowings of 35% of our collateralized assets.  
 
 
-15-
 
Employees
 
As of December 31, 2017, the Company employed a total of 71 employees including 3 trainees, 0 employees on disability and 4 part-time employees which represents 2 full-time-equivalents. None of our employees are members of a labor union.
 
Financial Information about Foreign and Domestic Operations and Export Sales
 
Markets outside of North America are an important factor in the Company’s business strategy. Any business that operates on a worldwide basis and conducts its business in one or more local currencies is subject to the risk of fluctuations in the value of those currencies against the dollar, as well as foreign economic conditions. Such businesses are also subject to changing political climates, differences in culture and the local practices of doing business, as well as North American and foreign government actions such as export and import rules, tariffs, duties, embargoes and trade sanctions. The Company does not regard these risks, however, as a significant deterrent to our strategy to introduce our MEDITE product lines to foreign markets in the future. The Company’s current operations include payments and receivables in the three currencies of USD, EURO and Yen. For USD and Euro we try to naturally hedge them by having revenues and expenses in both currencies. Even in not handling other currencies directly, the exchange rates in both USD and Euro may influence our costs and prices directly and/or indirectly. The Company intends to adopt strategies to minimize the risks of changing economic and political conditions within the foreign countries we intend to do business.
 
During the fiscal year ended December 31, 2017, the Company had direct foreign operations in Germany and distributed to approximately 80 countries in total. 
 
Item 1A.
Risk Factors
 
Not applicable as small reporting company.
 
Item 2.
Properties
 
The Company occupies a total of 72,513 square feet of property of which 24,324 is leased space. The owned building at the address Wollenweberstrasse 12, 31303 Burgdorf, Germany, has 43,884 square feet. In addition, until recently we occupied a leased neighborhood building with an additional 11,302 square feet in space for manufacturing. As of March 31, 2018, we have vacated this building and consolidated all Burgdorf operations and personnel into the main building. Since February 2016, the Company leased a second German manufacturing facility in Nussloch for the microtomy manufacturing with leased space of 4,305 square feet. The headquarter facility at the address 4203 SW 34th Street, Orlando, FL 32811, U.S. with a space of 5,520 square feet is leased until July 31st, 2018, and the research laboratory facility at address Unit 306, 888 E. Belvidere Road, Grayslake, IL 60030, U.S. with 1,904 square feet with a lease expiration of June 30, 2018. The Company considers our facilities to be well utilized, well maintained, and in good operating condition. Further, we consider the facilities to be suitable for our intended purposes and to have capacities adequate to meet current and projected needs for our operations.  
 
The terms of our current leased facilities vary from 3 months’ notice for part of the German operation to a term agreement until June 30, 2018 for the laboratory facility in the Chicago area, and until July 31, 2018, for the Orlando facility. The monthly rent for the Orlando facility will increase from $2,488 currently to $ 2,563 per month in the last year of the lease. 
  
Item 3.
Legal Proceedings  
 
On November 13, 2016, the Company’s former CFO filed a complaint against the Company and certain officers and directors of the Company in the United States District Court for the Northern District of Illinois, Eastern Division, Case No. 1:16-cv-10554, whereby he is alleging (i) breach of the Illinois Wage and Protection Act, (ii) breach of employment contract and (iii) breach of loan agreement. He is seeking monetary damages up to approximately $1,665,972. The Company has denied the substantive allegations in the complaint and is vigorously defending the suit. Management believes that the claims set forth in the complaint against the Company are without merit. The Company has accrued wages and vacation of approximately $1.1 million and a $50,000 note payable to the former CFO. The presiding Federal Judge has referred the lawsuit to mediation. No settlement was reach during the April 2017 meditation. The Company has proactively initiated settlement offer. In August 2017, the parties reached a Settlement Term Sheet whereby a final forbearance and settlement agreement must be filed with the magistrate judge. On November 8, 2017 the Plaintiff filed a motion to compel settlement with a meeting before a magistrate judge on November 14, 2017. On February 20, 2018, the magistrate judge denied the settlement, concluding that a settlement did not exist because the parties had not agreed on all its constituent elements. On March 20, 2018 counsel for the defendants (the Company and certain former officers and directors) filed a motion with the Court to withdraw as counsel from Michael Ott, Michaela Ott and David Patterson due to a conflict of interest between certain parties. However, those parties consented to allow current counsel to continue representing the Company. On April 6, 2018, counsel for the defendants filed a motion for the Court to deny plaintiff’s motion to force the Company to accept an agreement based upon the August 2017 Settlement Term Sheet. On April 22, the judge ruled in favor of the Company and denied plaintiff’s motion to compel.
  
Item 4.
Mine Safety Disclosures
 
Not Applicable.
 
 
 
-16-
 
PART II
 
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Market Information
 
MEDITE common stock is quoted under the symbol “MDIT” on the OTCQB. The OTCQB is the middle tier of the three marketplaces for trading over-the-counter stocks provided and operated by the OTC Markets Group.
 
The following table lists the high and low bid information for our common stock for the periods indicated, as reported on the OTCQB. These quotations reflect inter-dealer prices, may not include retail mark-ups, mark-downs, or commissions, and may not reflect actual transactions.
 
Year Ended December 31, 2017
 
High
 
 
Low
 
1st Quarter
 $0.88 
 $0.30 
2nd Quarter
 $0.81 
 $0.38 
3rd Quarter
 $0.55 
 $0.41 
4th Quarter
 $0.76 
 $0.25 
 
    
    
Year Ended December 31, 2016
    
    
1st Quarter
 $0.71 
 $0.26 
2nd Quarter
 $0.89 
 $0.39 
3rd Quarter
 $0.89 
 $0.48 
4th Quarter
 $1.15 
 $0.55 
 
Holders
 
As of March 31, 2018, the Company had approximately 242 record holders of shares of our common stock.
 
Dividends
 
The Company has not paid a cash dividend on shares of MEDITE common stock, and our Board of Directors is not contemplating paying dividends at any time in the foreseeable future. The terms of certain of our securities, including our Series B, C, and E preferred stock, prohibit the Company from declaring any dividends on our common stock (or any other stock junior to such security) except for dividends payable in shares of stock of the Company of any class junior to such security, or redeem or purchase or permit any subsidiary to purchase any shares of common stock or such junior stock, or make any distributions of cash or property among the holders of the common stock or any junior stock by the reduction of capital stock or otherwise, if any dividends on the security are then in arrears.
 
The Company has no contingent obligation to pay cumulative dividends on any series of convertible preferred stock as of March 31, 2018.
 
Stock Transfer Agent
 
MEDITE’s stock transfer agent is Computershare Shareowner Services, 199 Water Street, 26th Floor, New York, New York, 10038 and its telephone number is (212) 805-7100.
 
Recent Sales of Unregistered Securities
 
In January, 2018 the Company raised $150,000 in additional capital under the same terms as described in the Subordinate Convertible Notes see Note 6. 
 
Also in January, 2018 the Company received a term sheet for additional debt financing, consisting of a convertible note with an initial conversion price of $0.075 per share.  Each $0.075 invested also receives one Common Stock share.  The Convertible Notes are subordinate to the GBP debt described in the GPB Debt Holdings II, LLC (“GPB”) Convertible Notes Payable see Note 6, have a 5-year maturity date and bear a 12% annual interest rate, payable semi-annually.  The Company received $1,955,000 in capital and issued 26,066,667 common stock shares under these terms as of May 17, 2018.
 
 
 
-17-
 
The Company filed a Form D on March 7, 2017, initiating a total offering of $4,250,000, of which $2,555,000 in stock subscriptions was received by the Company as of December 31, 2017, representing the purchase of 5,110,000 shares of common stock to 23 investors at $0.50/share.
 
On November 2, 2016, the Company filed a Form D Notice of Exempt Offering of Securities for up to $3,000,000 (“$3 Million Form D”). The Company received $411,915, as an initial funding of this offering at $0.50 a share, by selling 823,830 shares of common stock. The offering is subject to a up to 7.5% commission paid to their broker/dealers totaling $30,894 plus warrants of 7.5% coverage at $0.50 conversion price per share, with a term of 5 years. The offering closed prior to December 31, 2016.
 
During June 2016, the Company issued 292,167 shares of common stock to directors and consultants for accrued fees totaling to $274,870 as follows. The Company issued 68,750, 55,462, 68,750 shares of common stock to our director John Abeles for $55,000, Augusta Ocana for $44,370 and former director Alexander Miley for $55,000, respectively. The Company issued 63,125 shares of common stock to Northlea Partners, LLC, for the accrued fees of $50,500, a Partnership that John Abeles is the General Partner. The Company issued 20,455 shares of common stock for accrued fees of $45,000 and 15,625 shares of common stock for $25,000 of fees to consultants.
 
On March 15, 2016, the Board of Directors approved the renegotiated terms with the warrant holders to remove the anti-dilution feature in the Warrants for the warrants received increasing from 250,000 to 500,000 with a fixed exercise price of $0.80 from $1.60 per share. During January 2017, these warrants were amended with a fixed exercise price of $0.50.
 
During 2015, the Company issued 240,625 shares at $1.60 for proceeds of $385,000. On February 23, 2015, Ventana Medical Systems agreed to convert the Series “D” Preferred Stock, Stated and Liquidation value, $525,000 and accrued dividends of $656,250 into 12,100 shares of the Company’s unregistered common stock.
 
During 2015, the Company issued 1,086,250 shares of common stock at $1.60 for proceeds of $1,739,400 to the President of UNIC Medical of China. UNIC is the Company’s distributor in China and other Asian countries. In addition, the Company issued Michaela Ott and Michael Ott the remaining shares of 156,250 each, total of 312,500 shares, to complete the 15,000,000 shares required in conjunction with a 2014 purchase agreement.
 
 On December 31, 2015, the Company entered into a Securities Purchase Agreement (the “2015 Purchase Agreement”) with seven individual accredited investors  (collectively the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers secured promissory notes in the aggregate principal amount of $500,000 with interest accruing at an annual rate of 15% (the “Note(s)”) and warrants to purchase up to an aggregate amount of 250,000 shares of the common stock, par value $0.001) per share, of the Company (the “Warrant(s)”).  The Notes mature on the earlier of the third month anniversary date following the Closing Date, as defined in the Note, or the third business day following the Company’s receipt of funds exceeding one million dollars from an equity or debt financing, not including the financing contemplated under the 2015 Purchase Agreement. The Notes are secured by the Company’s accounts receivable and inventories held in the United States. The Warrants have an initial exercise price of $1.60 per share, which are subject to adjustment, and are exercisable for a period of five years.  If the Notes are not redeemed by the Company on maturity, the Purchasers are entitled to receive 10% of the principal balance of the Notes outstanding in warrants for every month that the Notes are not redeemed.  On March 31, 2016, these Notes matured and were not repaid.  Therefore the Notes were in default on April 1, 2016.  The Company agreed to pay the Purchasers 10% of the principal balance of the Notes in warrants until the Notes are repaid.  On March 15, 2016, the Board of Directors approved the renegotiated terms to increase the warrants issued to the Purchasers from a total of 250,000 warrants to 500,000 for certain considerations. The Notes are secured by the Company’s accounts receivable and inventories held in the United States. In January 2017 the Company extended the term of the Notes in default on April 1, 2016 to June 30, 2017, reduced the price on the warrants issued from $0.80 to 0.50.
 
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
 
None.
 
Item 6.
Selected Financial Data
 
Not applicable.
 
 
 
 
 
-18-
 
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Overview
 
MEDITE Cancer Diagnostics, Inc. (the “Company”, “it”, “we”, or “us”), formerly CytoCore, Inc., specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. These premium medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. The total global anatomic pathology market (including segments not addressed by the Company) was $17.3 billion in 2016, projected to grow at an annual rate of 6.5% to $30.3 billion by 2025. The well-established brand of MEDITE Cancer Diagnostics is well received and remains a professional description of the Company’s business. The Company’s trading symbol is “MDIT”.
 
In 2017 we focused on implementation of several growth opportunities including enhanced distribution of core products through focused sales and distribution channel(s), newly developed and patent pending and issued assays, new laboratory devices and several marketing projects like the Chinese standardization projects for histology and cytology.  The Company is optimistic about recent marketing efforts focusing on larger laboratory chains and other important strategic relationships. At the end of 2017 the Company had 64 employees in Germany and the U.S., a distribution network to over 80 countries and a wide range of products for anatomic pathology, histology and cytology laboratories available for sale.
 
The Company experienced continued delay in financing during 2017, which has impacted the delivery of sales due to availability of raw materials, parts, and work in progress inventory and the needed investment in that inventory. The Company originally anticipated total sales in 2017 of approximately $12 million with the assumption that the timing of the scheduled capital raise would happen earlier in the year. Due to the delay in the capital raise, the Company revised its target to $7 million.
 
The Company’s cytology product line, revenue declined in Europe (non-Gyn and Gyn applications) during 2017, related to a shortage of working capital as described above. In the U.S. the Company is moving forward with the submission of an application to the FDA for SureThin Gyn applications. Once approved we can compete with the dominant suppliers in this $600 million market and target major strategic lab partners. The impact of the gynecology segment SureThin solution in the U.S. and China market will drive significant new revenue and gross margin improvement opportunities in 2018.
 
The developed and U.S. patented self-collection device SoftKit will target the growing POC (Point of Care) market. Growth in this area is due to consumer-driven health care requirements and the necessity to support and address incremental patient population needs for screening and ongoing diagnostic tests. SoftKit addresses exactly this market requirement. SoftKit is planned to be sold through various marketing channels that serve the gynecology physician consumer health and emerging post-acute care as the influence of clinical labs are expanded. Initially the SoftKit is targeted at the uterine cancer/HPV and STD screening market. The next phase of testing will include cervical screening.
 
Management believes that 2017 and 2018 developments allow us to more fully leverage the products and biomarker solutions emerging from the CytoCore component of MEDITE. The first entry is the introduction of the SureCyte (fluorogenic) instant staining, offering tremendous lab efficiencies and enhanced patient care through the use of SureCyte. C1 is the first of many new offerings under the SureCyte brand.
 
Development of MEDITE’s breast cancer risk assessment product – BreastPap – was discontinued in 2017. While initial assessment of market interest was high, further study and discussion with market players revealed a low market opportunity.  
 
The Company operates in one industry segment for cancer diagnostics instruments and consumables for histology and cytology laboratories.
 
Definition:
Histology - Cancer diagnostics based on the structures of cells in tissues
Cytology - Cancer diagnostics based on the structures of individual cells
 
Cancers and precancerous conditions are defined in terms of structural abnormalities in cells. For this reason, cytology is widely used for the detection of such conditions while histology is typically used for the confirmation, identification and characterization of the cellular abnormalities detected by cytology. Other diagnostics methods such as marker-based assays provide additional information that can supplement, but which cannot replace cytology and histology. The trend towards more personalized treatment of cancer increases the need for cytology, histology and assays for identifying and testing the best treatment alternatives. We believe that this segment will therefore be increasingly important for future development of strategies to fight the “cancer epidemic” (World Health Organization: World Cancer Report 2014) which expects about a 50 % increase in cancer cases worldwide within the next 20 years.
 
 
-19-
 
This segment sees a trend toward, and demand for, higher automation for more throughput in bigger laboratories, process standardization between laboratories, digitalization of cell and tissue slides, and computer aided diagnostic systems, while also looking for cost reductions in the face of increasing competition and reimbursement pressure. In the US the Patient Protection and Affordable Care Act has been cited as a national example for the industry. More people have health insurance and therefore can afford early cancer screening, while at the same time the payers for health care continue looking for cost reductions.
 
MEDITE acts as a one-stop-shop for histology (also known as anatomic pathology) laboratories either as part of a hospital, as part of a chain of laboratories or individually. It is one out of only four companies offering all equipment and consumables for these laboratories worldwide. The MEDITE brand stands for innovative and high-quality products – most equipment made in Germany – and competitive pricing.
 
For the cytology market, MEDITE offers a wide range of consumable products and equipment; for liquid-based-cytology which is an important tool in cancer screening and detection in the field of cervical, bladder, breast, lung and other cancer types. It also developed an innovative, easy to use standardized staining solutions, and a very innovative and effective early cancer detection marker-based assays. These new developments are cost effective solutions able to replace more expensive competitive products, and therefore are also becoming the first choice for the growing demand in emerging countries.
 
All of the Company’s operations during the reporting period were conducted and managed within this segment, with management teams reporting directly to our Chief Executive Office. For information on revenues, profit or loss and total assets, among other financial data, attributable to our operations, see the consolidated financial statements included herein. Further during this 2017 period we added key personnel with excellent historical performance in new product commercialization, sales development and internal operations improvement.
  
Outlook
 
Due to promising innovative new products for cancer risk assessment and an increasing number of distribution contracts executed in the past few years, management believes the profitability and cash-flow of the business will grow and improve. However, significant on-going operating expenditures may be necessary to manufacture and market new and existing products to achieve the accelerated sales growth targets outlined in the Company’s business plan. To realize the planned growth potential, management will focus its efforts on 1.) Finishing and gaining approval for the products currently under development and 2.) Increase direct sales in the U.S. and continue to expand Chinese market sales by broadening the Company’s collaborations with the local distributor UNIC. We also will work on continuously optimizing manufacturing capacity to increase our gross margin. Implementation of our plans will be contingent upon securing substantial additional debt and/or equity financing. If the Company is unable to obtain additional capital or generate profitable sales revenues, we may be required to curtail product development and other activities. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty.
 
Currently, the Company’s sales primarily are generated in Euro currency. While in 2017 the average USD/Euro exchange rate was approximately 1.13, in 2018 it has steadily increased to 1.22. 
 
The Company believes the combination of MEDITE Enterprise, Inc. with CytoCore, Inc. will expedite the development and marketability of CytoCore’s cytology products which include collection devices, image analysis software, special stains and immuno-assays. Currently, the recent launch of new products, the positive impact from several new initiatives, and some recently executed distribution contracts in the U.S., Europe and China are some primary positive factors assisting growth.
 
Critical Accounting Policies and Significant Judgments and Estimates
 
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
 
The Company believes that the critical accounting policies affect our more significant estimates and judgments used in the preparation of our consolidated financial statements under Note 2.
 
 
 
 

 
 
-20-
 
Results of Operations
 
Fiscal Year Ended December 31, 2017 as compared to Fiscal Year Ended December 31, 2016 (Dollars in thousands)
Revenue
 
Total revenues of $6,813 for the year ended December 31, 2017, compared $9,238 for the year ended December 31, 2016, represented a decrease in revenues of $2,425 or 26.3%. The Company’s manufactured instruments decreased $1,140, a decrease of 24.8% in 2017 as compared to 2016 revenues. The related histology consumables revenue declined by $849, or 26.4% in 2017 from the 2016 level. Cytology products revenue decreased by $436, or 30.3% in 2017 compared to 2016. In all cases these declines were the result of cash constraints impacting the delivery of own manufactured equipment, OEM equipment and consumables. As of December 31, 2017, the Company had a backlog of approximately $1.2 million.
 
Costs and Expenses
 
Cost of Revenues
 
Cost of revenues represents the cost of the product sold, freight, and other costs of selling our products. Cost of revenues totaled $6,651 (97.6% of revenue) for the year ended December 31, 2017, compared to $5,608 (60.7% of revenue) for the year ended December 31, 2016. This mainly resulted from a higher share of sales of manufactured equipment with slightly higher margins versus merchandise supply goods in 2017 compared to 2016. The reason for the significant decrease in the gross profit was due to the write-off of inventory and the slowdown in production due to operational funding issues in 2017.
 
Research and Development
 
Research and development expenses are an important part of the Company’s business to keep our existing products competitive and to develop new innovative solutions with interesting market potential that will help us grow future revenues. These expenses include research work for cancer marker consumables and developing work, including engineering and industrial design, for histology and cytology laboratories worldwide. Major parts of these expenses are payroll-related costs for in-house scientific research, mechanical and electrical engineering, instrument related software development staff, prototype expenses and material purchased for R&D.
 
For the 2017 fiscal year, research and development expenses decreased to $1,188 compared $1,477 for 2016. The Company continues to expend resources necessary to grow our product offerings. 
 
Selling, General and Administrative
 
For the year ended December 31, 2017, SG&A expenses were $5,161 compared to $3,600 in 2016, an increase of $1,561. The increase in SG&A was mainly the result of increased payroll expense of $596, increased bad debt expense of $313 for reserving of accounts receivable, increased legal fees for litigation of $146, increased travel expenses of $106 and increased marketing and insurance expense of $137.
 
Operating Loss
 
The operating loss of $6,480 for 2017 compared to $1,661 in 2016 is due to the lower sales resulting from lack of production capacity, due to lack of working capital. The loss is also attributed to significantly lower margin attributed to production absorption of fixed costs resulting from lower production volume.
             
Interest Expense, net
 
Interest expense was $849 for 2017 compared to $694 in 2016 an increase of 22.3% due to the increase in GPB debt in 2017.
 
Income Tax
 
The income tax benefit in 2017 was $487 compared to a benefit of $132 in 2016. The income tax benefit in 2017 resulted from the lower federal statutory rate.
 
Net Loss
 
The increase in net loss for the year ended December 31, 2017 of $6,811 compared to the year ended December 31, 2016 of $2,163 is due to the lower net contribution on sales and higher selling, general and administrative and interest expense for the year ended December 31, 2016, as discussed above.              
 
 
 
-21-
 
Liquidity and Capital Resources
 
For the year ended December 31, 2017, we used net cash in operations of approximately $3.6 million compared to $1.1 million for the same period in 2016. During 2017 cash used in operations consisted of loss from operations, offset by non-cash transactions for warrants issued related to secured promissory notes. Collections for accounts receivable, higher accounts payable and accrued expense balances offset by increased balances in inventory contributed to the use of funds for the 2017 period. During 2016, cash used in operations consisted of loss from operations, offset by non-cash transactions for warrants issued related to secured promissory notes. Collections for accounts receivable, higher accounts payable and accrued expense balances offset by increased balances in inventory contributed to the use of funds for the 2016 period.
 
For the year ended December 31, 2017, net cash used in investing activities was $134 compared to $115 for the same period in 2016.  The improvement in this activity relates to lower purchases of equipment in 2017 compared to 2016.
 
For the year ended December 31, 2017, financing activities provided $3,465 compared to $700 for the same period in 2016. The Company sold 5,060,000 shares of common stock for $2,344 and had net proceeds from convertible debt of $4,895 and had net repayment on lines of credit of $2,812 during the year 2017. The Company sold 873,830 shares of common stock for $406 during the fourth quarter of 2016, net of $31 of issuance costs. In May 2016, the Company issued $150 of additional secured promissory notes.
 
In January, 2018 the Company raised $150,000 in additional capital under the same terms as described in the Subordinate Convertible Notes see Note 6. 
 
Also in January, 2018 the Company received a term sheet for additional debt financing, consisting of a convertible note with an initial conversion price of $0.075 per share.  Each $0.075 invested also receives one Common Stock share.  The Convertible Notes are subordinate to the GBP debt described in the GPB Debt Holdings II, LLC (“GPB”) Convertible Notes Payable see Note 6, have a 5-year maturity date and bear a 12% annual interest rate, payable semi-annually.  The Company received $1,955,000 in capital and issued 26,066,667 common stock shares under these terms as of May 17, 2018.
 
In 2016, the Company’s lines of credit and term notes funded $135 and in 2015 repaid $802.    During 2015, MEDITE GmbH reduced its outstanding indebtedness under its master credit line with Hannoversche Volksbank from Euro 1.8 million ($1.9 million as of December 31, 2016) to Euro 1.3 million ($1.4 million as of December 31, 2016). The remaining line of credit of Euro 1.1 million ($1.2 million as of December 31, 2016) has no maturity date and the Company believes that the bank will continue working with the Company as it attempts to raise additional capital resources through debt or equity. Should the bank look for additional reductions to the Company’s line of credit, the Company believes that it can obtain bank financing elsewhere at equivalent terms or if necessary raise the funds needed through operations. The balance at December 31, 2016 of this master credit line is $46 below the required balance. 
 
The Company must contemplate continuation as a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business.  At December 31, 2017, the Company’s cash and restricted cash balance was $490 and its operating losses for the year ended December 31, 2017 and 2016, have used most of the Company’s liquid assets, but have a negative working capital balance of $318 at the end of 2017 compared to a negative working capital of approximately $2,003 as of December 31, 2016. The improvement in working capital is based upon the company's ability to raise capital as explained in the financing activities above.
 
Accrued salaries, vacation and related expenses at December 31, 2017, includes amounts owed to the former CFO approximately $1.1 million and amounts owed to both the Michaela and Michael Ott totaling approximately $125.  Included in advances – related parties are amounts owed to the Company’s former CFO and former CEO and Chairman of the Board of $50 at December 31, 2017, and 16 Euros, ($19 as December 31, 2017) and 71 Euros, ($85 as December 31, 2017) related to two short term bridge loans made to the Company by its former CEO and current COO of the Company. The Company is working with the current executives to establish a payment plan. See further discussion regarding the legal proceedings with the Company’s former Chief Financial Officer.
 
The Company’s security agreement with its lender has provided borrowings of 35% of our collateralized assets.  
 
Management continues to expand its product offerings and has also expanded its sales and distribution channels during 2017.
 
 
-22-
 
If management is unsuccessful in completing its equity financing, they will begin negotiating with some of their major vendors and lenders to extend the terms of their debt and also evaluate certain expenses that have been implemented for the Company’s growth strategy.    However, there can be no assurance that the Company will be successful in these efforts. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
Item 8.                                 Financial Statements and Supplementary Data
 
Our consolidated financial statements and notes thereto for the years ended December 31, 2017 and 2016, together with the reports of our Independent Registered Public Accounting Firm are filed as part of this Annual Report on Form 10-K commencing on page F-1 and are incorporated herein by reference.
 
Item 9.                                  Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
 
On January 5, 2017, upon the recommendation of the Company’s Audit Committee, the Board of Directors of the Company dismissed WithumSmith+Brown, PC (“Withum”) as the Company’s independent registered public accounting firm.
 
On January 11, 2017 (the “Engagement Date”), upon the recommendation of the Company’s Audit Committee, the Board of Directors of the Company engaged KMJ Corbin & Company LLP (“KMJ”) as the Company’s independent registered public accounting firm, beginning with the period ended December 31, 2016.
 
During the Company's two most recent fiscal years, the subsequent interim periods thereto, and through the Engagement Date, neither the Company nor anyone on its behalf consulted KMJ regarding either (1) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements; or (2) any matter regarding the Company that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
 
Item 9A.                              Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in our Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
 
As of December 31, 2017, our management carried out an assessment, under the supervision of and with the participation of our Chief Executive Officer who is also acting as the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b).  As a result of this assessment, the Chief Executive Officer and acting Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2017 because of the material weakness described in “Management’s Report on Internal Control Over Financial Reporting” below.
 
Management's Annual Report on Internal Control Over Financial Reporting
 
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act).   Under the supervision and with the participation of its management, including its Chief Executive Officer, who serves as our principal executive officer, and is also its acting Chief Financial Officer, who serves as our principal financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting. In making this assessment, we used the criteria set forth in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on management’s assessment based on the criteria of the COSO, it concluded that, as of December 31, 2017, its internal control over financial reporting is not effective at the reasonable assurance level.
 
 
 
-23-
 
The Company’s internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the U.S. Our internal control over financial reporting includes those policies and procedures that:
 
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
 
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the U.S., and that receipts and expenditures of the Company are being made only in accordance with authorization of our management and directors; and
 
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.
 
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.
 
During the audit of our consolidated financial statements for the year ended December 31, 2017, management determined that we had material weaknesses in our quarterly and annual financial close processes. The material weaknesses related to our company was due to not having the adequate personnel to address the reporting requirements of a public company and to fully analyze and account for our transactions. We do not believe that this material weakness has resulted in deficient financial reporting because we have worked through the audit process to review our transactions to assure compliance with professional standards.
 
This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting.  Management’s report was not subject to attestation by our registered public accounting firm pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, which permits us to provide only management’s report in this annual report.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in our internal control over financial reporting during the quarter ended December 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
Item 9B
Other Information
 
None.
 


 
 
-24-
 
PART III
 
Item 10.
Directors, Executive Officers, and Corporate Governance
 
Board of Directors and Executive Officers
 
Name
 
Age
 
Positions with the Company
 Stephen L. Von Rump
 
60
 
 Chief Executive Officer, interim Chief Financial Officer, Treasurer and Secretary
Susan Weisman
 
57
 
Chief Financial Officer (Resigned January 2018)
Greg Fortunoff
 
48
 
Director
John H. Abeles, M.D.
 
72
 
Director
Joel Kanter
 
61
 
Director
W. Austin Lewis, IV
 
42
 
Chairman of Board, Head of Audit Committee (since February 12, 2016)
 
Board of Directors
 
The Company believes that our Board should be composed of individuals with sophistication and experience in many substantive areas that impact its business. We believe that experience, qualifications, or skills in the following areas are most important: accounting and finance; design, innovation and engineering; strategic planning; human resources and development practices; and board practices of other corporations. These areas are in addition to the personal qualifications described in this section. The Company believes that all of our current Board members possess the professional and personal qualifications necessary for board service and have highlighted particularly noteworthy attributes for each Board member in the individual biographies below. The principal occupation and business experience, for at least the past five years, and educational background of each current director is as follows:
 
Stephen Von Rump, Age 60, Chief Executive Officer
 
Stephen Von Rump is Chief Executive Officer for MEDITE Cancer Diagnostics, as well as the Managing Director of MEDITE GmbH in Germany. He has over 20 years of broad operational experience including R&D for software, electronic and mechanical development; manufacturing, technical service, project and quality management, intellectual property, regulatory activities, sales and marketing, and finance. Mr. Von Rump has 8 years of experience in medical device technology and telehealth platforms, specifically focused on the remote care of elderly and others living with chronic conditions. He has extensive international experience, leading and working with companies in Europe, Asia and North America.
 
Mr. Von Rump has founded/cofounded several companies including Giraff Technologies in Sweden, which developed the world’s first comprehensive remote care platform to include fully mobile telepresence; and BeHere Corporation in the U.S., a 360o videoconferencing and collaboration platform. He was formerly the CEO of VTEL, then the second largest videoconferencing provider in the world and included a global telemedicine practice.
 
Mr. Von Rump is a designated “expert” with the European Commission in the health technology sector, evaluating R&D funding proposals for the Horizon 2020 Programme. He is a veteran of four multi-national grant projects in the EU, and through these projects has twice won the AAL Forum’s annual Innovation Award. He holds an M.S. Electrical Engineering degree from Washington University in the U.S.
 
Susan Weisman. Age 56, Chief Financial Officer
 
On April 26, 2017 Susan Weisman was appointed Chief Financial Officer of the Company. Ms. Weisman is a Finance Executive with over 30 years of progressive experience in consulting, executive positions with both public and private companies and various industries, including financial services, technology, real estate, medical services and manufacturing. She has an extensive history of increasing responsibility, achievement of growth in all positions across product/service/technology.
 
 
-25-
 
From August 2008 until the present, Ms. Weisman operated Finance and Strategic Consultants, LLC, where she provided advisory services to the Company as well as a healthcare service provider and a healthcare technology, various other technology companies, financial services companies as well as real estate and various other industries. From September 20008 to October 2010 Ms. Weisman worked for AFC, LLC., an investment company of Mitsui & Co (USA) as Chief Financial Officer, Acting Chief Executive Officer and Chief Liquidation Officer a sub-prime auto finance company reporting to Mitsui & Co (USA). From September 2007 to August 2008, Ms. Weisman was the Chief Financial Officer and Chief Operating Officer for CU Business Capital, LLC. From 2004 to 2007, a credit union service organization.
 
Ms. Weisman was Chief Financial Officer and Director of Coach Industries Group, a company required to file reports with the Securities and Exchange Commission, a financial services company offering lease finance, insurance, independent contractor settlement to commercial fleet operators, as well as the manufacturer of modified commercial vehicles. From 1990 to 2000, Ms. Weisman was Controller and acting CFO of a $4.2 Billion savings bank holding company, BankAtlantic Bancorp, a company required to file reports with the Securities and Exchange Commission which included BankAtlantic, a federal savings bank, BankAtlantic Development Corporation, a real estate development company, Ryan, Beck & Co. an investment banking company and various internet start-up investments.
 
From 1986 to 1990 Ms. Weisman worked for KPMG, LLC, a global accounting firm. Ms. Weisman obtained a B.S. Degree in Economics from City University of New York - Brooklyn College. Ms. Weisman is a certified public accountant – New York (inactive status). Mr. Weisman resigned as the Chief Financial Officer in January 2018.
 
Greg Fortunoff, Age 48, Director
 
Greg Fortunoff is an experienced manufacturing and financial executive with over 25-year experience of healthcare investing experience. Since 2014 through the present, Mr. Fortunoff has been the owner of Jeftex Corporation and is responsible for overseeing the operations of this 87-year-old textile converter company. From 2009 until 2014, Mr. Fortunoff was the owner of G-2 Trading, LLC before selling the company in 2014. Mr. Fortunoff managed the daily operations of this equity trading firm with $100,000,000 in positions. From 2006 to 2011, Mr. Fortunoff served as a Board Member of American Medical Alert, Inc., a small cap medical device and communication company which was ultimately sold at a premium to a private company. In 1992, Mr. Fortunoff earned a B.A. degree in Marketing from Syracuse University. Mr. Fortunoff is not currently, nor has he been an officer or director of any company required to file reports with the Securities Exchange Commission. 
 
John H. Abeles, M.D., Age 72, Director
 
John H. Abeles, M.D, has been a director of the Company since May 1999. Dr. Abeles is President of MedVest, Inc., a venture capital and consulting firm he founded in 1980.   He is also General Partner of Northlea Partners, Ltd., a family investment partnership.   Dr. Abeles previously served as a senior medical executive at Sterling Drug Company, Pfizer, Inc. and Revlon Healthcare, Inc. and subsequently was a medical analyst at Kidder, Peabody & Co.   Dr. Abeles is a director of several companies operating in the medical device and healthcare fields.   Dr. Abeles possesses particular knowledge and experience in medical education, venture capital and finance, and the pharmaceutical industry that strengthen the Board’s collective qualifications, skills, and experience. Dr. Abeles invested $50,000 through Northlea Partners, Ltd.in the Company’s secured promissory notes and received 75,000 warrants to purchase shares of common stock.
 
Joel Kanter, Age 61, Director
 
Mr. Joel Kanter has served as President of Windy City, Inc., a privately held investment firm, since July 1986.
From 1989 to November 1999, Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (NMS: WNUT). Walnut Financial’s primary business focus was the provision of different forms of financing to small business, by providing equity financing to start-up and early stage development companies, providing bridge financing to small and medium-sized companies, and providing later stage institutional financing to more mature enterprises. The Company was sold to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million.
 
Mr. Kanter serves on the Board of Directors of several public companies including Magna-Labs, Inc., formerly involved in the development of a cardiac MRI device; and WaferGen which is engaged in the development, manufacturing and sales of state of the art systems for gene expression, genotyping and stem cell research for the life sciences, pharmaceutical drug discovery and development for biomarker discovery and diagnostic products industries.
 
 
 
-26-
 
Mr. Kanter also serves on the Boards of several private concerns including Fibralign Coproration, which makes a collagen based BioBridge that allows for veins and other tissue to regrow where it has otherwise ceased to exist; First Hand Tickets, Inc, which is a concierge secondary ticket sales company; First Wave Technologies, which has developed a product for hospitals and nursing homes that makes crushing pills much easier for the large patient base that cannot swallow them, and is developing a new ventilator for use in hospitals that will provide greater mobility and lower costs in addition to enhanced inhalation therapy; Mercator MedSystems, Inc. a company specializing in medical injection devices; Minds Eye Entertainment Ltd. which is a Canadian film production company; and Serpin Pharma, a Company that has developed several peptides that appear capable of having dramatic impacts on diseases resulting from inflammation.
 
Mr. Kanter is also a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, and a former Trustee at the Georgetown Day School in Washington, D.C., as well as of the Union Institute & Univesity. He is also the current Board Chair of the Black Student Fund, and a past President of the Independent School Chairpersons Association. He is an Executive Committee Member of the Kennedy Center’s National Committee on the Performing Arts, and Chair’s that organization’s Education Committee. He also serves on the Virginia Governor’s Virginia Israel Advisory Board.
 
William Austin Lewis IV, Age 42, Director
 
William Austin Lewis IV currently serves as the CFO and Director of Paid Inc. (PAYD). Mr. Lewis also serves as a member of the Audit Committees and Compensation Committees for MAM Software, Inc. (MAMS), and FlouroPharma Medical, Inc. (FPMI).   Since 2004, Mr. Lewis has served as Chief Executive Officer of Lewis Asset Management Corporation, an investment management company he founded, where he is also the Portfolio and Chief Investment Officer of the Lewis Opportunity Fund, one of the funds under management. Prior to founding Lewis Asset Management, Mr. Lewis held a variety of positions with investment firms, including Puglisi & Co., Thompson Davis & Co., and Branch Cabell & Company. Mr. Lewis holds a Bachelor of Science in Finance and a Bachelor of Science in Financial Economics from James Madison University.
 
Section 16(a) Beneficial Ownership Reporting Compliance
 
Section 16(a) of the Exchange Act requires the Company’s executive officers and directors, and holders of more than 10% of the outstanding shares of its common stock, to file initial reports of ownership and reports of changes in ownership with the Commission.  They are also required to furnish the Company with copies of all Section 16(a) forms that they file with the SEC. Based solely on the Company’s review of copies of such forms received by it and/or any written representations from such persons that no other reports were required with respect to 2017, we believe that all Section 16(a) filing requirements were satisfied in a timely fashion during our fiscal year ended December 31, 2017, except that Drs. Abeles, Ocana and Mr. Lewis failed to timely file Form 4s.
 
Code of Ethics
 
The Company has adopted its Code of Ethics and Business Conduct for Officers, Directors and Employees that applies to all of our officers, directors and employees, including its principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions. The Company filed the code as an exhibit to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2003, as filed with the Commission on April 14, 2004. The Code of Ethics is also available on our website at www.medite-group.com.
 
Board of Directors and Committee Information
 
The Board of Directors currently has one standing committee – the Audit Committee. The Compensation Committee and the Nominating and Corporate Governance Committee are going to be re-established with current Directors of the Board in the future.
 
Audit Committee
 
The Audit Committee currently consists of Mr. Lewis (Chairman, since February 12, 2016) who replaced Mr. Milley (Chairman until February 12, 2016) and Dr. Abeles, both of whom are independent under applicable independence requirements.   The Board of Directors has determined that Mr. Lewis qualifies as an “audit committee financial expert” as defined in Item 407(d) (5) (ii) of Regulation S-K promulgated under the Exchange Act.
 
 
 
-27-
 
The Audit Committee acts pursuant to a written charter, which charter authorizes the committee’s overview of the financial operations and management of the Company, including a required review process for all quarterly, annual, and special filings with the Commission, review of the adequacy and efficacy of the accounting and financial controls of the Company as well as the quality of accounting principles and financial disclosure practices, and communications with the Company’s independent registered public accounting firm and members of financial management. A copy of the Audit Committee’s charter was filed as an appendix to the Company’s definitive proxy statement for its 2007 annual stockholders meeting, as filed with the SEC on May 15, 2007, and is available on our website. The Audit Committee met 4 times in 2017.
 
Stockholder Nominations
 
There were no material changes to the procedures by which stockholders may recommend nominees to the Company’s board of directors during the 2017 fiscal year.
 
Item 11.
Executive Compensation
 
Summary Compensation Table
 
The following table sets forth the compensation earned by the Company’s principal executive officer, and each of the Company’s two most highly compensated executive officers other than the principal executive officer whose compensation exceeded $100,000 (collectively, the “Named Executive Officers”), during the years ended December 31, 2017 and 2016.
 
Name and Principal Position (a)
 
Year (b)
 
 
Salary ($) (c)
 
 
Bonus ($) (d)
 
 
Stock awards
($) (e)
 
 
Option
awards ($) (f)
 
David Patterson
2017
  108,462 
  62,850 
  - 
  - 
CEO (Resigned November 2017)
2016
  18,462 
  - 
  125,000(1)
  - 
Stephen Von Rump
2017
  78,462 
  17,140 
  86,000(2)
  - 
CEO
2016
  - 
  - 
  - 
  - 
Susan Weisman
2017
  79,846 
  17,140 
  162,000(2)
  - 
Chief Financial Officer (Resigned January 2018)
2016
  - 
  - 
  - 
  - 
Jeff Rencher
2017
  78,462 
  17,140 
  64,500(2)
  - 
Chief Marketing and Business Development Office
2016
  - 
  - 
  - 
  - 
 
Name and Principal Position (a)
 
Year (b)
 
 
Nonequity incentive plan compensation
($)(g)
 
 
Nonqualified deferred compensation
earnings ($) (h)
 
 
All other
compensation (i)
 
 
Total ($) (j)
 
David Patterson
2017
 
 
 
$
 
 
$
 
 $171,312 
CEO (Resigned November 2017)
2016
  - 
  - 
  - 
  143,462 
Stephen Von Rump
2017
  - 
  - 
  - 
  181,602 
CEO
2016
  - 
  - 
  - 
  - 
Susan Weisman
2017
  - 
  - 
  - 
  258,986 
Chief Financial Officer (Resigned January 2018)
2016
  - 
  - 
  - 
  - 
Jeff Rencher
2017
  - 
  - 
  - 
  160,102 
Chief Marketing and Business Development Officer
2016
  - 
  - 
  - 
  - 
 
(1)
Stock award vests over a 3 year period. Represents 250,000 shares of common stock issued in October 2016 pursuant to his employment agreement. The bonus for 2017 was paid, but is under review as it was not approved by the Board of Directors.
(2)
Stock award vests over a 3 year period. Represents 200,000, 200,000 and 150,000 shares of common stock for Susan Weisman, Stephen Von Rump and Jeff Rencher respectively, issued in 2017 pursuant to their employment agreements.
 
 
-28-
 
Outstanding Equity Awards at Fiscal Year-End
 
On October 31, 2016, pursuant to his employment agreement, David E. Patterson was granted 250,000 restricted shares of the Company’s common stock (the “Shares”). The Shares will vest in three (3) equal installments on each of the first three annual anniversary dates of Mr. Patterson’s appointment, so long as he remains employed by the Company through each such vesting date. Mr. Patterson resigned as CEO in November 2017. On April 26, 2017, Susan Weisman was granted 200,000 restricted shares of the Company’s common stock (the “Shares”). The Shares would vest starting April 25, 2018 as long as she is still with the Company. Ms. Weisman resigned from the Company January 2, 2018 and thereby forfeited the shares. On May 4, 2017, Stephen Von Rump was granted 200,000 restricted shares of the Company’s common stock (the “Shares”). The Shares begin vesting May 3, 2018. On May 4, 2017, Jeff Rencher was granted 150,000 restricted shares of the Company’s common stock (the “Shares”). The shares begin vesting May 3, 2018.
 
Equity Incentive Plan and Employee Stock Purchase Plan
 
N/A
 
Potential Payments Upon Termination or Change-in-Control
 
The Company does not offer or have in place any formal severance, change in control or similar compensation programs for our officers or employees. Rather, we individually negotiate with those employees for whom such compensation is deemed necessary. The Company’s restricted stock grants to its CEO and other officers does require an accelerated vesting upon a change in control. We are obligated to provide warrants to our outside directors upon the occurrence of certain changes in control. For more information, see “Compensation of Directors” below.
                              
Compensation of Directors
 
The following table sets forth certain information regarding the compensation of directors for our 2017 fiscal year.
 
Employee
Name
 
Director
Stock Option Plan
 
 
Fees Earned or
Paid in Cash ($)
 
 
 
Total
 
W. Austin Lewis
 $148,659(2)
  20,000(1)
 $168,659 
John Abeles
  123,883(2)
  - 
  123,883 
Eric Goehausen
  123,883(2)
  - 
  123,883 
Augusto Ocana
  123,882(2)
  - 
  123,882 
Greg Fortunoff
  - 
  - 
  - 
Joel Kanter
  - 
  - 
  - 
John H. Abeles, M.D.
  - 
  - 
  - 
 
(1) 
As Chairman of the Audit Committee, $5,000 a quarter is included in fees earned. Mr. Lewis’s balance of $20,000 was accrued and unpaid as of December 31, 2017.
 
 
(2)
The Company’s 2017 Director Stock Option Plan (the “Plan”) for the issuance of up to 3,000,000 options to grant common stock to the Company’s employees, directors and consultants was adopted pursuant to the written consent of holders of a majority of the Company’s common stock obtained as of March 7, 2017 and was considered approved on April 21, 2017. The Company amended the Plan on August 1, 2017 and was considered approved on September 1, 2017 to include certain technical changes and increased the shares from 3,000,000 to 5,000,000. At September 30, 2017, the Company issued 2.1 million of non-qualified stock options with a term of 10 years, with a strike price above the market on the date of issuance of $0.50, to vest one-third upon issuance, one-third atthe beginning of the calendar year of service, or January 1, 2018 and one-third on January 1, 2019, to the Board of Directors valued at $520,307 using the Black Scholes Model. Included in selling, general and administrative in the accompanying consolidated statement of operations and comprehensive loss for the period is $346,872 for the year ended December 31, 2017, related to the non-qualified options issued to the Board of Directors.
 
 
 
 
 
-29-
 
Narrative Disclosure to Director Compensation Table
 
The Company paid its Director of the Audit Committee a quarterly fee of $5,000 as compensation for his service on its board of directors. In addition, in 2017 the directors were compensated by the issuance of 2,100,000 options which were allocated 600,000 to Austin Lewis, 500,000 each to John Abeles, Augusto Ocana and Eric Goehausen. The total fair market value of $520,307 was allocated equally per option issued.
 
For information on other consideration received by directors or their affiliates from the Company, see “Transactions with Related Persons, Promoters and Certain Control Persons” in Item 13 below.
 
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
Common Stock
 
The following table sets forth certain information, as of December 31, 2017, with respect to holdings of our common stock by (i) each person known by us to be the beneficial owner of more than 5% of the total number of shares of common stock outstanding as of such date, (ii) each of our directors and executive officers, and (iii) all directors and executive officers as a group. Except as otherwise indicated, the address of each person is c/o MEDITE Cancer Diagnostics, Inc., 4203 SW 34th Street, Orlando, FL 32811, U.S.   
 
Name and Address of Beneficial Owner
 
Amount and
Nature of
Beneficial 
Ownership (1)
 
 
 
 
 
Percent
of Class
 
 
 
 
 
 
 
 
 
 
 
Michaela Ott
  15,000,000 
(2)
  17.46%
 
    
       
    
Michael Ott
  15,000,000 
(3)
  17.46%
 
    
       
    
Robert F. McCullough, Jr.
  1,676,907 
(4)
  3.90%
 
    
   
    
Augusto Ocana, M.D. and J.D.
  679,885 
(10)
  1.58%
 
    
       
    
Austin Lewis
  12,917,093 
(6)
  30.08%
 
    
   
    
Stephen Von Rump
  200,000 
       
  * 
 
    
       
    
Jeff Rencher
  150,000 
       
  * 
 
    
   
    
John H. Abeles, M.D.
  1,808,381 
(5)
  4.21%
 
    
   
    
Greg Fortunoff
  2,077,812 
(7)
  4.84%
 
    
   
    
Joel Kanter
  509,148 
(8)
  1.19%
 
    
   
    
Eric Goehausen
  500,000 
(9)
  1.16%
 
    
       
    
All beneficial owners and management as a group (11 persons)
  35,519,226 
       
  82.70%
 
  * Less than one percent
 
(1)
Unless otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares set forth opposite such person’s name. With respect to each person or group, percentages are calculated based on the number of shares beneficially owned, including shares that may be acquired by such person or group within 60 days of December 31, 2017 upon the exercise of stock options, warrants or other purchase rights, but not the exercise of options, warrants or other purchase rights held by any other person. There were 56,655,580 shares of common stock outstanding as of the close of business on May 17, 2018.
 
 
-30-
 
(2)
Includes: (i) 7,500,000 shares held by Mrs. Ott’s husband, Michael Ott.
 
(3)
Includes: (i) 7,500,000 shares held by Mr. Ott’s wife, Michaela Ott.
 
(4)
Includes an aggregate 1,662 shares owned by various trusts of which Mr. McCullough is trustee as follows: MJM Educational Trust (150) shares, PFM Educational Trust (150 shares), CDM Educational Trust (150) shares and the MPC Trust (1,212 shares).
 
(5)
Includes: (i) 192,518 shares owned by Northlea Partners, Ltd., of which Dr. Abeles is General Partner; and (ii) 1000 shares of common stock awarded in 2009 that have not yet been issued. Dr. Abeles disclaims beneficial ownership of all shares owned by, or issuable to, Northlea Partners except shares attributable to his 1% interest in Northlea Partners as General Partner. Includes 28,000 warrants to purchase shares of common stock at exercise prices between $4.00 and $6.00 for Mr. Abeles and 33,750 to Northlea Partners with similar terms. Includes Northlea Partners 75,000 warrants to purchase shares of common stock at an exercise price of $0.80 a share related to the secured promissory notes dated May 26, 2016. Also includes 500,000 options to purchase common stock at an exercise price of $0.50.
 
(6)
Includes: 260,000 warrants to purchase shares of common stock at an exercise price of $0.50 a share related to the issuance of secured promissory notes issued on December 31, 2015 and 52,597 convertible warrants to purchase common stock at an exercise price of $0.30. Also includes 600,000 options to common stock at an exercise price of $0.50.
 
(7)
Includes: 494,478 warrants convertible warrants to purchase common stock at an exercise price of $0.60.
 
(8)
Includes: 169,724 warrants convertible warrants to purchase common stock at an exercise price of $0.60.
 
(9) 
Includes: 500,000 options to purchase common stock at an exercise price of $0.50.
 
(10) 
Includes: 500,000 options to purchase common stock at an exercise price of $0.50.
 
Series E Convertible Preferred Stock
 
The following table sets forth certain information with respect to holdings of our Series E Convertible Preferred Stock by (i) each person known by us to be the beneficial owner of more than 5% of the total number of shares of the Company’s Series E Convertible Preferred Stock outstanding as of such date, (ii) each of our directors and executive officers, and (iii) all directors and executive officers as a group.  
 
Name and Address of Beneficial Owner (1)
 
Amount and
Nature of
Beneficial 
Ownership (2)
 
 
 
 
 
Percent
of Class
 
Kevin F. Flynn June 1992 Non-Exempt Trust
120 South LaSalle Street
Chicago, IL 60602
  464 
(3)
  35.03%
 
    
       
    
Rolf Lagerquist
4522 CO Road 21 NE
Elgin, MN 55932
  139 
(4)
  10.51%
 
(1)
No executive officers or directors own any shares of Series E Convertible Preferred Stock.
 
(2)
Unless otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares set forth opposite such person’s name. With respect to each person or group, percentages are calculated based on the number of shares beneficially owned, including shares that may be acquired by such person or group upon the exercise of stock options, warrants or other purchase rights, but not the exercise of options, warrants or other purchase rights held by any other person. There were 19,022 shares of Series E Convertible Preferred Stock outstanding as of the close of business on March 31, 2017.
 
(3)
Converts into 464 shares of common stock, including shares issuable upon payment of cumulative dividends.
 
(4)
Converts into 139 shares of common stock, including shares issuable upon payment of cumulative dividends.
 
 
-31-
 
Equity Compensation Plan Information
 
Plan category
 
Number of securities
to be issued upon
exercise of outstanding
options, warrants and
rights
 
 
Weighted-average exercise price of outstanding options, warrants and rights
 
 
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
 
 
 
(a)
 
 
(b)
 
 
(c)
 
Equity Compensation Plans Approved by Security Holders
 
 
 
 
 
 
 
 
 
2017 Employee/Consultant Common Stock Compensation Plan
  2,100,000(2)
  0.50 
  2,900,000 
 
    
    
    
Equity Compensation Plans Not Approved by Security Holders
    
    
    
Warrants issued for officer, director and employee compensation (1)
  390 
 $1.00 
   
 
    
    
    
Total
  390 
 $1.00 
   
 
(1)
The Company has issued warrants in lieu of cash payment for employment services, for achieving certain goals or for other corporate reasons. During fiscal year 2015, it issued no employee warrants to that non-executive employee which his contract was terminated by April 2014.
 
(2)  
The Company’s 2017 Director Stock Option Plan (the “Plan”) for the issuance of up to 3,000,000 options to grant common stock to the Company’s employees, directors and consultants was adopted pursuant to the written consent of holders of a majority of the Company’s common stock obtained as of March 7, 2017 and was considered approved on April 21, 2017. The Company amended the Plan on August 1, 2017 and was considered approved on September 1, 2017 to include certain technical changes and increased the shares from 3,000,000 to 5,000,000. At September 30, 2017, the Company issued 2.1 million of non-qualified stock options with a term of 10 years, with a strike price above the market on the date of issuance of $0.50, to vest one-third upon issuance, one-third at the beginning of the calendar year of service, or January 1, 2018 and one-third on January 1, 2019, to the Board of Directors valued at $520,307 using the Black Scholes Model. Included in selling, general and administrative in the accompanying consolidated statement of operations and comprehensive loss for the period is $346,872 for the year ended December 31, 2017, related to the non-qualified options issued to the Board of Directors.
 
Changes in Control
 
None.
 
Item 13.
Certain Relationships and Related Transactions, and Director Independence
 
The following section sets forth information regarding transactions since January 1, 2016, or any currently proposed transactions, between the Company and certain related persons. For more information on the compensation received by the Company’s directors and officers, and the beneficial ownership of equity securities of the Company by such individuals, see Item 11 “Executive Compensation” and Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” above.
 
 
 
-32-
 
Robert F. McCullough, Jr., former Chief Financial Officer and Director.
 
 On October 26, 2016 the Board accepted the resignation of Robert F. McCullough, Jr. as Chairman of the Board. On November 5, 2016, The Board of the Company held a special meeting and dismissed Robert F. McCullough, Jr. from his position as Chief Financial Officer, Secretary and Treasurer. On December 5, 2016, the Company issued and Information Statement, to holders of the Company’s outstanding common stock, as of the close of business on November 22, 2016, pursuant to Rule 14c−2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The purpose of the Information Statement was to inform the common stockholders that we have obtained the written consent of the holders of the majority of the issued and outstanding shares of our Common Stock, to remove Robert F. McCullough, Jr., effective immediately, from the position of Director of the Company. Mr. McCullough loaned to the Company an aggregate $159,500 during the 2013 fiscal year. $40,000 was repaid in 2015, and $20,000 was repaid during 2016. The Company owes an aggregate outstanding balance of $50,000 as of December 31, 2016 which is payable upon demand. The Company is in litigation with Mr. McCullough.
 
William Austin Lewis IV, Director and Chairman of the Audit Committee
 
Prior to being a Director of the Company, Mr. Lewis invested $100,000 in the Company’s secured promissory notes and received 50,000 warrants to purchase the Company’s common stock at $1.60.  The warrants have a term of five years with anti-dilution features.  Subsequent to Mr. Lewis becoming a Director, the Company agreed to issue an additional 50,000 warrants and reduce the price of the warrants to $0.80 for the renegotiated terms, eliminating the anti-dilution clause in the warrants.  The Company has not repaid the secured promissory notes on its maturity date of March 31, 2016.  Mr. Lewis will receive 10% of his principal balance outstanding in warrants for every month that the notes are not repaid. At December 31, 2016 Mr. Lewis has 190,000 warrants outstanding. In January 2017, the Company amended the warrants and reduced the exercise price of the warrants to $0.50 a share.
 
Settlement of Fees and Payment of Consulting Fees and Commissions to Directors
 
During the years ended December 31, 2017 and 2016, we engaged in the following transactions with its directors:
The Company’s 2017 Employee/Consultant Common Stock Compensation Plan (the “Plan”) for the issuance of up to 3,000,000 options to grant common stock to the Company’s employees, directors and consultants was adopted pursuant to the written consent of holders of a majority of the Company’s common stock obtained as of March 7, 2017 and was considered approved on April 21, 2017. The Company amended the Plan on August 1, 2017 and was considered approved on September 1, 2017 to include certain technical changes and increased the shares from 3,000,000 to 5,000,000. At September 30, 2017, the Company issued 2.1 million of non-qualified stock options with a term of 10 years, with a strike price above the market on the date of issuance of $0.50, to vest one-third upon issuance, one-third at the beginning of the calendar year of service, or January 1, 2018 and one-third on January 1, 2019, to the Board of Directors valued at $520,307 using the Black Scholes Model. Included in selling, general and administrative in the accompanying condensed consolidated statement of operations and comprehensive loss for the period is $346,872 for the year ended December 31, 2017, related to the non-qualified options issued to the Board of Directors.
 
During the second quarter of 2016, the Company settled its outstanding directors’ fees in common stock. The Company issued 68,750, 55,442, 68,750 shares of common stock to our director John Abeles for $55,000, Augusta Ocana for $44,370 and former director Alexander Miley for $55,000, respectively. The Company issued 63,125 shares of common stock to Northlea Partners, LLC, for the accrued fees of $50,500, a Partnership that John Abeles is the General Partner.
 
During the period ended October 31, 2016, the Company paid it CEO David Patterson, through his consulting firm David Patterson, LLC, $45,000 in consulting fees prior to becoming CEO. The Company also paid David Patterson, LLC $20,000 as a bonus to David Patterson, LLC for the period from July 2016 through October 2016.
 
Director Independence
 
Upon consideration of the criteria and requirements regarding director independence set forth in Rules 5000(a)(19) and 5605(a)(2) of the rules of the NASDAQ Stock Market, the Company has determined that Dr. Abeles and Mr. Lewis are independent. With regard to the Company’s audit committee, the board of directors has determined that Dr. Abeles and Mr. Lewis, who constitute all members of the audit committee, are independent with respect to the independence criteria for audit committee members set forth in Rule 5605(c)(2) of the rules of the NASDAQ Stock Market and Rule 10A-3(b)(1) of the Exchange Act.
 
 
-33-
 
 
Item 14.
Principal Accountant Fees and Services
 
On January 5, 2017 (the “Engagement Date”), upon the recommendation of the Company’s Audit Committee, the Board of Directors of the Company KMJ Corbin & Company LLP (“KMJ”) as the Company’s independent registered public accounting firm, beginning with the period ended December 31, 2016. WithumSmith+Brown, PC (“Withum”) served as the Company’s independent registered public accounting firm until the January 5, 2017, for the fiscal year ended December 31, 2015.
               
Fees
 
The following table presents fees for the professional services rendered by KMJ and WSB for fiscal years 2017 and 2016, respectively:
 
Services Performed
 
2017
 
 
2016
 
Audit Fees (1)
 $97,375 
 $144,344 
Audit-Related Fees (2)
  - 
  14,500 
Tax Fees (3)
  - 
  21,011 
All Other Fees
  -
 
  - 
Total Fees
 $97,375 
 $179,855 
 
(1)
Audit fees represent fees billed for professional services rendered for the audit of our annual financial statements and review of the financial statements included in the Company’s quarterly reports or services that are normally provided in connection with statutory and regulatory filings or engagements.
(2)
Audit-related fees represent fees billed for assurance and related services reasonably related to the performance of the audit or review of our financial statements not reported in (1) above, including those incurred in connection with securities registration and/or other issues resulting from that process.
(3)
Tax fees represent fees billed for professional services rendered for tax compliance, tax advice and tax planning services.
 
Pre-Approval Policies
 
As required by applicable law, the Audit Committee is responsible for the appointment, compensation, retention and oversight of the work of the Company’s independent registered public accounting firm. In connection with such responsibilities, the Audit Committee is required, and it is the Audit Committee’s policy, to pre-approve the audit and permissible non-audit services (both the type and amount) performed by its independent registered public accounting firm to ensure that the provision of such services does not impair the firm’s independence, in appearance or fact.
 
 The Audit Committee pre-approved all audit services provided to the Company during fiscal 2017.
 
 
 
 
-34-
 
PART IV
 
Item 15.
Exhibits and Financial Statement Schedules
 
Documents filed as part of this Annual Report
 
The following items are filed as part of this report.
 
 
(*) Denotes an exhibit filed herewith.
 
 Exhibit No.
 
 Description
 
 
 
 
Certification of the Chief Executive Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
Certification of the Chief Financial Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
Certification of the Chief Executive Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
Certification of the Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
101.INS
 
XBRL Instance Document  
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document  
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document  
 
 
 
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document  
 
 
 
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document  
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document  
 
* Filed herewith
** To be filed by amendment 
 
 
 
-35-

 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MEDITE Cancer Diagnostics, Inc.
 
 
 
 
By:
/s/ Stephen Von Rump
 
 
Stephen Von Rump
 
 
Chief Executive Officer
Principal Executive Officer
 
 
 
 
Date: 
May 17, 2018
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
 
 
 
 
 
/s/ Stephen Von Rump  
 
Chief Executive Officer  
 
May 17, 2018
Stephen Von Rump  
 
(Principal Executive Officer)  
 
 
 
 
 
 
 
/s/ Stephen Von Rump 
 
Acting Chief Financial Officer 
 
May 17, 2018
Stephen Von Rump
 
 (Principal Financial Officer)
 
 
 
 
 
 
 
/s/ W. Austin Lewis IV
 
Chairman of the Board
 
May 17, 2018
W. Austin Lewis IV
 
And Director
 
 
 
 
 
 
 
/s/ John Abeles, M.D.
 
Director
 
May 17, 2018
/s/ John Abeles, M.D.
 
 
 
 
 
 
 
 
 
/s/Joel Kanter
 
Director
 
May 17, 2018
Joel Kanter
 
 
 
 
 
 
 
 
 
/s/Greg Fortunoff
 
Director
 
May 17, 2018
Greg Fortunoff
 
 
 
 

 
 
-36-
 
 
MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES
 
INDEX TO FINANCIAL STATEMENTS
 
 
 
 
 
 
 
 
  
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
To the Board of Directors and Stockholders of
MEDITE Cancer Diagnostics, Inc. and Subsidiaries
 
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of MEDITE Cancer Diagnostics, Inc. and Subsidiaries (the “Company”) as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2017, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
 
Going Concern
 
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has experienced recurring losses from operations, has negative operating cash flows during the year ended December 31, 2017 and is dependent on its ability to raise capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management's plans in regard to these factors are also described in Note 1. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
Basis for our Opinion
 
These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
 
/s/ KMJ Corbin & Company LLP
 
We have served as the Company’s auditor since 2017.
Costa Mesa, California
May 17, 2018
 
 
 
MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share and per share amounts)
 
  
 
December 31,
 
 
 
2017
 
 
2016
 
Assets
 
 
 
 
 
 
Current Assets:
 
 
 
 
 
 
Cash
 $73 
 $108 
Restricted cash
  417 
  - 
Accounts receivable, net of allowance for doubtful accounts of $439 and $123
  453 
  1,346 
Inventories
  2,403 
  3,811 
Prepaid expenses and other current assets
  118 
  79 
Total current assets
  3,464 
  5,344 
 
    
    
Property and equipment, net
  1,778 
  1,557 
Acquired in-process research and development
  4,620 
  4,620 
Trademarks, trade names
  1,240 
  1,240 
Goodwill
  4,658 
  4,658 
Other assets
  196 
  151 
Total assets
 $15,956 
 $17,570 
 
    
    
Liabilities and Stockholders’ Equity
    
    
Current Liabilities:
    
    
Accounts payable and accrued expenses
 $3,252 
 $3,164 
Secured lines of credit and current portion of long-term debt
  50 
  3,214 
Notes due to employees, current portion
  326 
  681 
Advances – related parties
  154 
  288 
Total current liabilities
  3,782 
  7,347 
 
    
    
Long term debt, net of current portion and debt discounts
  4,869 
  60 
Notes due to employees, net of current portion
  45 
  135 
Deferred tax liability
  1,485
  2,005 
Total liabilities
  10,181
  9,547 
 
    
    
Commitments and Contingencies
    
    
 
    
    
Stockholders’ Equity:
    
    
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 shares issued and outstanding as of December 31, 2017 and 2016 (liquidation value of all classes of preferred stock $2,624 and $2,533 as of December 31, 2017 and 2016, respectively)
  962 
  962 
Common stock, $0.001 par value; 100,000,000 shares authorized, 28,906,081 and 22,421,987 issued and outstanding as of December 31, 2017 and 2016, respectively
  29 
  23 
Additional paid-in capital
  13,750 
  9,366 
Stock subscription
  - 
  25 
Treasury stock
  (327)
  (327)
Accumulated other comprehensive loss
  (444)
  (642)
Accumulated deficit
  (8,195)
  (1,384)
Total stockholders’ equity
  5,775
  8,023 
 
    
    
Total liabilities and stockholders’ equity
 $15,956 
 $17,570 
  
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 
 
MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Dollars in thousands, except share and per share amounts)
 
 
 
 
 
Years Ended December 31,
 
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 $6,813 
 $9,238 
Cost of revenues
  6,651 
  5,608 
Gross profit
  162 
  3,630 
 
    
    
Operating Expenses:
    
    
Depreciation and amortization expense
  293 
  214 
Research and development
  1,188 
  1,477 
Selling, general and administrative
  5,161 
  3,600 
Total operating expenses
  6,642 
  5,291 
Operating loss
  (6,480)
  (1,661)
 
    
    
Other Income (Expenses):
    
    
Interest expense, net
  (849)
  (694)
Loss on extinguishment of notes due to employees
  (158)
  - 
Other income, net
  189 
  60 
Total other expenses, net
  (818)
  (634)
 
    
    
Loss before income taxes
  (7,298)
  (2,295)
 
    
    
Income tax benefit
  (487)
  (132)
Net loss
  (6,811)
  (2,163)
Preferred dividend
  (91)
  (91)
Net loss available to common stockholders
 $(6,902)
 $(2,254)
 
    
    
Loss per share
    
    
Net loss available to common stockholders
 $(6,902)
 $(2,254)
Basic and diluted loss per share
 $(0.26)
 $(0.11)
Weighted average basic and diluted shares outstanding
  26,436,064 
  21,423,535 
 
    
    
Consolidated statements of comprehensive loss
    
    
Net loss
 $(6,811)
 $(2,163)
Other comprehensive income (loss):
    
    
Foreign currency translation adjustments
  198 
  (33)
Comprehensive loss
 $(6,613)
 $(2,196)
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 
 MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Dollars in thousands, except share and per share amounts)
 
 
 
 
 
Preferred Stock
 
 
Common Stock
 
 
 
 
 
 
 
 
Additional
 
 
Retained Earnings
 
 
Accumulated Other
 
 
Total
 
 
 
 
 
Par Value $0.001
 
 
Par Value $0.001
 
 
Treasury Stock
 
 
Paid-In
 
 
Stock
 
 (Acumulated 
 
Comprehensive
 
 
Stockholders’
 
      
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Subscriptions
 
 
  Deficit)
 
 
Loss
 
 
Equity
 
January 1, 2016
 
  198,355 
 $962 
  21,055,990 
 $21 
  (19,209)
 $(327)
 $8,340 
 $- 
 $779 
 $(609)
 $9,166 
Reclassification of warrant liability
  - 
  - 
  - 
  - 
  - 
  - 
  90 
  - 
  - 
  - 
  90 
Warrants issued for secured promissory notes and penalties
    
  - 
  - 
  - 
  - 
  - 
  278 
  - 
  - 
  - 
  278 
Issuance of common stock for services
  - 
  - 
  292,167 
  1 
  - 
  - 
  271 
  - 
  - 
  - 
  272 
Sale of common stock, net 
  - 
  - 
  823,830 
  1 
  - 
  - 
  380 
  - 
  - 
  - 
  381 
Common stock subscription
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  25 
  - 
  - 
  25 
Issuance of common stock for compensation based awards
    
    
  250,000 
  - 
  - 
  - 
  7 
  - 
  - 
  - 
  7 
Other comprehensive loss  
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (33)
  (33)
Net loss  
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (2,163)
  - 
  (2,163)
December 31, 2016  
  198,355 
  962 
  22,421,987 
  23 
  (19,209)
  (327)
  9,366 
  25 
  (1,384)
  (642)
  8,023 
 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Estimated fair value of warrants issued in connection with secured promissory notes for debt discount and penalties
  - 
  - 
  - 
  - 
  - 
  - 
  795 
  - 
  - 
  - 
  795 
Repricing of warrants
 
  - 
  - 
  - 
  - 
  - 
  - 
  64 
  - 
  - 
  - 
  64 
Shares issued to consultants
  - 
  - 
  110,000 
  - 
  - 
  - 
  55 
  - 
  - 
  - 
  55 
Shares issues for services related to convertible debt
  - 
  - 
  182,927 
  - 
  - 
  - 
  75 
  - 
  - 
  - 
  75 
Conversion of notes payable and accrued interest 
  - 
  - 
  371,167 
  - 
  - 
  - 
  185 
  - 
  - 
  - 
  185 
Estimated fair value of warrants issued for settlement of employee notes payable
  - 
  - 
  - 
  - 
  - 
  - 
  389 
  - 
  - 
  - 
  389 
Sale of common stock, net 
  - 
  - 
  5,060,000 
  5 
  - 
  - 
  2,338 
  - 
  - 
  - 
  2,343 
Issuance of subscribed common stock 
  - 
  - 
  50,000 
  - 
  - 
  - 
  25 
  (25)
  - 
  - 
  - 
Issuance of restricted common stock 
  - 
  - 
  710,000 
  1 
  - 
  - 
  - 
  - 
  - 
  - 
  1 
Stock-based compensation 
  - 
  - 
  - 
  - 
  - 
  - 
  458 
  - 
  - 
  - 
  458 
Other comprehensive income
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  198 
  198 
Net loss  
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (6,811)
  - 
  (6,811)
December 31, 2017
  198,355 
 $962 
  28,906,081 
 $29 
  (19,209)
 $(327)
 $13,750 
 $- 
 $(8,195)
 $(444)
 $5,775
 
 
The accompanying notes are an integral part of these consolidated financial statements.

 
 
MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
 
 
 
 
Years Ended December 31,
 
 
 
2017
 
 
2016
 
Cash flows from operating activities:
 
 
 
 
 
 
Net loss
 $(6,811